



**MAPLE LEAF FOODS INC.**

**Interim Report to Shareholders**  
For the Second Quarter Ended  
June 30, 2022

# Management's Discussion and Analysis

1	Financial Overview	1
2	Response to COVID-19	1
3	Operating Review	2
4	Restructuring and Other Related Costs	4
5	Income Taxes	5
6	Acquisitions and Divestitures	5
7	Capital Resources	5
8	Capital Expenditures	7
9	Normal Course Issuer Bid	7
10	Cash Flow and Financing	7
11	Goodwill	8
12	Financial Instruments	8
13	Transactions with Related Parties	9
14	Share Capital	9
15	Other Matters	9
16	Maple Leaf Centre for Action on Food Security	9
17	Summary of Quarterly Results	10
18	Significant Accounting Policies	11
19	Internal Controls Over Financial Reporting	12
20	Outlook	12
21	Non-IFRS Financial Measures	13
22	Forward-Looking Statements	19
23	About Maple Leaf Foods Inc.	22

# Management's Discussion and Analysis

All dollar amounts are presented in Canadian dollars unless otherwise noted.

August 3, 2022

## 1. FINANCIAL OVERVIEW

(\$ millions except earnings per share) (Unaudited)	As at or for the Three months ended June 30,			As at or for the Six months ended June 30,		
	2022	2021	% Change	2022	2021	% Change
Sales	\$ 1,195.1	\$ 1,158.9	3.1 %	\$ 2,321.7	\$ 2,211.9	5.0 %
Net (Loss) Earnings	\$ (54.6)	\$ 8.8	(722.4)%	\$ (40.9)	\$ 56.5	(172.5)%
Basic (Loss) Earnings per Share	\$ (0.44)	\$ 0.07	(728.6)%	\$ (0.33)	\$ 0.46	(171.7)%
Adjusted Operating Earnings <sup>(i)</sup>	\$ 23.6	\$ 58.3	(59.5)%	\$ 39.7	\$ 109.8	(63.8)%
Adjusted Earnings per Share <sup>(i)</sup>	\$ 0.00	\$ 0.29	(100.0)%	\$ 0.03	\$ 0.56	(94.6)%
Adjusted EBITDA - Meat Protein Group <sup>(i)</sup>	\$ 104.1	\$ 131.2	(20.7)%	\$ 201.6	\$ 255.1	(21.0)%
Sales - Plant Protein Group	\$ 40.8	\$ 48.1	(15.2)%	\$ 85.7	\$ 90.7	(5.5)%
Free Cash Flow <sup>(i)</sup>	\$ (70.6)	\$ (135.9)	48.1 %	\$ (257.4)	\$ (331.1)	22.3 %
Construction Capital <sup>(i)</sup>				\$ 665.8	\$ 720.8	(7.6)%
Net Debt <sup>(i)</sup>				\$ (1,421.2)	\$ (1,068.2)	33.0 %

<sup>(i)</sup> Refer to section 21. Non-IFRS Financial Measures of this document for the definition of these non-IFRS measures.

Sales for the second quarter of 2022 were \$1,195.1 million compared to \$1,158.9 million last year, an increase of 3.1%, driven by higher sales in the Meat Protein Group, partially offset by lower sales in the Plant Protein Group. For more details on sales performance by operating segment, refer to section 3. Operating Review.

Year-to-date sales for 2022 were \$2,321.7 million compared to \$2,211.9 million last year, an increase of 5.0%, due to similar factors as noted above.

Net loss for the second quarter of 2022 was \$54.6 million (\$0.44 per basic share) compared to earnings of \$8.8 million (\$0.07 per basic share) last year. The net loss resulted from weaker commercial performance due to cost inflation and labour challenges, as well as higher restructuring costs and start-up expenses.

Year-to-date net loss for 2022 was \$40.9 million (\$0.33 per basic share) compared to earnings of \$56.5 million (\$0.46 per basic share) last year. The net loss resulted from weaker commercial performance due to cost inflation and labour challenges, as well as higher restructuring costs and start-up expenses.

Adjusted Operating Earnings for the second quarter of 2022 were \$23.6 million compared to \$58.3 million last year, and Adjusted Earnings per Share for the second quarter of 2022 were \$0.00 compared to \$0.29 last year due to similar factors as noted above.

Year-to-date Adjusted Operating Earnings for 2022 were \$39.7 million compared to \$109.8 million last year, and Adjusted Earnings per Share for 2022 were \$0.03 compared to \$0.56 last year due to similar factors as noted above.

For further discussion on key metrics and a discussion of results by operating segment, refer to section 3. Operating Review below.

## 2. RESPONSE TO COVID-19

As an essential service, Maple Leaf Foods Inc. ("Maple Leaf Foods" or the "Company") is focused on protecting the health and well-being of its people, maintaining business continuity and broadening its social outreach. To manage through this unprecedented environment, the Company has taken a number of measures in its business and operating practices that include heightened safety policies and procedures, adopting a vaccination mandate for all employees and contractors, and close communication and collaboration with public health authorities, including hosting on-site vaccination clinics in 2021. The measures enacted to protect the health and safety of employees have increased the Company's current cost structure due to higher labour, personal protective equipment, sanitation and other expenses associated with the pandemic.

Overall, the Company believes its proactive and comprehensive efforts have, and should continue to mitigate adverse operational impacts. As the COVID-19 situation evolves, Maple Leaf Foods will continue to adapt and adopt best practices that prioritize the health and safety of its employees and the stability of the food supply. As part of Maple Leaf Foods' broader social responsibility since the pandemic began, the Company has provided extensive support to front-line staff, emergency food relief efforts and health care providers.

COVID-19 continues to have an impact on the global economy, leading to increased inflation, labour shortages and disruptions in the global supply chain. To date, the Company's leading brands, revenue management capabilities and robust supply chain have enabled it to mitigate these impacts. Maple Leaf Foods continues to monitor the ongoing environment and believes it is well-positioned to face these headwinds.

### 3. OPERATING REVIEW

Maple Leaf Foods has two reportable segments. These segments offer different products, with separate organizational structures, brands, financial, and marketing strategies. The Company's chief operating decision makers regularly review internal reports for these businesses: performance of the Meat Protein Group is based on revenue growth, Adjusted Operating Earnings and Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), while the performance of the Plant Protein Group in the short term is focused on obtaining Adjusted EBITDA neutral or better results.

The following table summarizes the Company's sales, gross profit, Selling, General and Administrative expenses ("SG&A"), Adjusted Operating Earnings, Adjusted EBITDA, and Adjusted EBITDA Margin by operating segment for the three months ended June 30, 2022 and June 30, 2021.

(\$ millions) <sup>(i)</sup> (Unaudited)	Three months ended June 30, 2022				Three months ended June 30, 2021			
	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total
<b>Sales</b>	\$ 1,160.2	40.8	(5.9)	\$ 1,195.1	\$ 1,117.5	48.1	(6.7)	\$ 1,158.9
<b>Gross profit (loss)</b>	\$ 136.0	(10.1)	(38.7)	\$ 87.2	\$ 167.0	0.3	(31.7)	\$ 135.7
<b>Selling, general and administrative expenses</b>	\$ 87.3	26.3	—	\$ 113.6	\$ 81.2	29.8	—	\$ 110.9
<b>Adjusted Operating Earnings<sup>(iii)(iv)</sup></b>	\$ 57.7	(34.0)	—	\$ 23.6	\$ 87.3	(29.1)	—	\$ 58.3
<b>Adjusted EBITDA<sup>(iii)(iv)</sup></b>	\$ 104.1	(30.0)	—	\$ 74.1	\$ 131.2	(25.5)	—	\$ 105.7
<b>Adjusted EBITDA Margin<sup>(iii)(iv)</sup></b>	9.0 %	(73.6)%	n/a	6.2 %	11.7 %	(53.1)%	n/a	9.1 %

<sup>(i)</sup> Totals may not add due to rounding.

<sup>(ii)</sup> Non-allocated includes eliminations of inter-segment sales and associated cost of goods sold, changes in the fair value of biological assets and derivatives, and non-allocated costs which are comprised of expenses not separately identifiable to reportable segments or are not part of the measures used by the Company when assessing a segment's operating results.

<sup>(iii)</sup> Refer to section 21. Non-IFRS Financial Measures of this document for the definition of these non-IFRS measures.

<sup>(iv)</sup> Certain comparative figures have been restated to conform with current year presentation.

The following table summarizes the Company's sales, gross profit, SG&A, Adjusted Operating Earnings, Adjusted EBITDA, and Adjusted EBITDA Margin by operating segment for the six months ended June 30, 2022 and June 30, 2021.

(\$ millions) <sup>(i)</sup> (Unaudited)	Six months ended June 30, 2022				Six months ended June 30, 2021			
	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total
<b>Sales</b>	\$ 2,249.6	85.7	(13.6)	\$ 2,321.7	\$ 2,131.2	90.7	(9.9)	\$ 2,211.9
<b>Gross profit (loss)</b>	\$ 266.9	(16.3)	(9.5)	\$ 241.1	\$ 333.1	0.4	(4.9)	\$ 328.6
<b>Selling, general and administrative expenses</b>	\$ 176.0	57.1	—	\$ 233.1	\$ 168.3	58.6	—	\$ 226.8
<b>Adjusted Operating Earnings<sup>(iii)(iv)</sup></b>	\$ 108.7	(68.9)	—	\$ 39.7	\$ 167.0	(57.1)	—	\$ 109.8
<b>Adjusted EBITDA<sup>(iii)(iv)</sup></b>	\$ 201.6	(60.7)	—	\$ 140.9	\$ 255.1	(49.9)	—	\$ 205.2
<b>Adjusted EBITDA Margin<sup>(iii)(iv)</sup></b>	9.0%	(70.8)%	n/a	6.1%	12.0%	(55.0)%	n/a	9.3%

<sup>(i)</sup> Totals may not add due to rounding.

<sup>(ii)</sup> Non-allocated includes eliminations of inter-segment sales and associated cost of goods sold, changes in the fair value of biological assets and derivatives, and non-allocated costs which are comprised of expenses not separately identifiable to reportable segments or are not part of the measures used by the Company when assessing a segment's operating results.

<sup>(iii)</sup> Refer to section 21. Non-IFRS Financial Measures of this document for the definition of these non-IFRS measures.

<sup>(iv)</sup> Certain comparative figures have been restated to conform with current year presentation.

### Meat Protein Group

The Meat Protein Group is comprised of prepared meats, ready-to-cook and ready-to-serve meals, value-added fresh pork and poultry products that are sold to retail, foodservice and industrial channels, and agricultural operations in pork and poultry. The Meat Protein Group includes leading brands such as Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®, Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®, and many leading regional brands.

Sales for the second quarter of 2022 increased 3.8% to \$1,160.2 million compared to \$1,117.5 million last year. Sales growth was driven by pricing action to mitigate inflation and a favourable mix-shift in product sales, including growth in sustainable meats and branded products, partially offset by lower sales volume.

Year-to-date sales for 2022 increased 5.6% to \$2,249.6 million compared to \$2,131.2 million last year. Sales growth was driven by pricing actions to mitigate inflationary cost increases and favourable mix-shift towards sustainable meats, branded products and growth in sales to the United States. These positive factors were partially offset by lower sales volume.

Gross profit for the second quarter of 2022 was \$136.0 million (gross margin<sup>(i)</sup> of 11.7%) compared to \$167.0 million (gross margin<sup>(i)</sup> of 14.9%) last year. Gross profit was negatively impacted by cost inflation, labour shortages, and pork market headwinds, partially offset by pricing action. Gross profit for the second quarter included start-up expenses of \$9.0 million (2021: \$1.5 million) associated with Construction Capital projects, which are excluded in the calculation of Adjusted Operating Earnings.

Year-to-date gross profit for 2022 was \$266.9 million (gross margin<sup>(i)</sup> of 11.9%) compared to \$333.1 million (gross margin<sup>(i)</sup> of 15.6%) last year. Gross profit was negatively impacted by operational and supply chain disruptions, inflationary cost increases, and pork market headwinds, partially offset by pricing action. Gross profit year-to-date included start-up expenses of \$17.7 million (2021: \$2.1 million) associated with Construction Capital projects, which are excluded in the calculation of Adjusted Operating Earnings.

SG&A expenses for the second quarter of 2022 were \$87.3 million compared to \$81.2 million last year. The increase in SG&A expenses was largely driven by the timing of advertising and promotional expenses and a gradual normalization of discretionary spending.

Year-to-date SG&A expenses for 2022 were \$176.0 million compared to \$168.3 million last year. The increase in SG&A expenses was driven by the timing of advertising and promotional expenses, a gradual normalization of discretionary spending and donations to support the relief efforts in Ukraine.

Adjusted Operating Earnings for the second quarter of 2022 were \$57.7 million compared to \$87.3 million last year, consistent with factors noted above.

Year-to-date Adjusted Operating Earnings for 2022 were \$108.7 million compared to \$167.0 million last year, consistent with factors noted above.

Adjusted EBITDA for the second quarter of 2022 were \$104.1 million compared to \$131.2 million last year, driven by factors consistent with those noted above. Adjusted EBITDA Margin for the second quarter was 9.0% compared to 11.7% last year, also driven by factors consistent with those noted above.

Year-to-date Adjusted EBITDA for 2022 were \$201.6 million compared to \$255.1 million last year, driven by factors consistent with those noted above. Year-to-date Adjusted EBITDA Margin for 2022 was 9.0% compared to 12.0% last year, also driven by factors consistent with those noted above.

### Plant Protein Group

The Plant Protein Group is comprised of refrigerated plant protein products, premium grain-based protein, and vegan cheese products sold to retail, foodservice and industrial channels. The Plant Protein Group includes the leading brands Lightlife® and Field Roast™.

Sales for the second quarter of 2022 decreased 15.1% to \$40.8 million compared to \$48.1 million last year. Excluding the impact of foreign exchange, sales decreased 18.4%, driven by lower volumes in retail products. This more than offset pricing action implemented to mitigate inflation and structural cost increases, and growth in foodservice volumes.

Year-to-date sales for 2022 decreased 5.5% to \$85.7 million compared to \$90.7 million last year. Excluding the impact of foreign exchange, sales decreased 7.5%, driven by lower volumes in retail products. This more than offset growth in foodservice volumes and pricing action implemented to mitigate inflation and structural cost increases.

Gross profit for the second quarter of 2022 was a loss of \$10.1 million (gross margin loss<sup>(i)</sup> of 24.7%) compared to income of \$0.3 million (gross margin<sup>(i)</sup> of 0.6%) last year. The decrease in gross profit was driven by inflationary costs and strategic investments in capacity ahead of anticipated demand, which resulted in increased overhead and short-term costs. This was partially offset by pricing action. Gross profit for the quarter also included start-up expenses of \$2.3 million (2021: \$0.4 million) associated with Construction Capital projects which are excluded in the calculation of Adjusted Operating Earnings

Year-to-date gross profit for 2022 was a loss of \$16.3 million (gross margin loss<sup>(i)</sup> of 19.1%) compared to income of \$0.4 million (gross margin<sup>(i)</sup> of 0.5%) last year. The decrease in gross profit was driven by inflationary costs and strategic investments in capacity ahead of anticipated demand, which resulted in increased overhead and short-term costs. This was partially offset by pricing action. Year-to-date Gross profit also included start-up expenses of \$4.5 million (2021: \$1.0 million) associated with Construction Capital projects which are excluded in the calculation of Adjusted Operating Earnings

SG&A expenses for the second quarter of 2022 were \$26.3 million (64.4% of sales) compared to \$29.8 million (61.9% of sales) last year. The decrease in SG&A expenses was primarily attributable to lower advertising expenses, partially offset by higher consulting and people costs.

Year-to-date SG&A expenses for 2022 were \$57.1 million (66.6% of sales) compared to \$58.6 million (64.6% of sales) last year. The decrease in SG&A expenses was primarily attributable to lower advertising expenses, partially offset by higher consulting and people costs.

Adjusted Operating Earnings for the second quarter of 2022 were a loss of \$34.0 million compared to a loss of \$29.1 million last year. The decrease in Adjusted Operating Earnings is consistent with the factors noted above.

Year-to-date Adjusted Operating Earnings for 2022 were a loss of \$68.9 million compared to a loss of \$57.1 million last year. The decrease in Adjusted Operating Earnings is consistent with the factors noted above.

<sup>(i)</sup> Gross margin is defined as gross profit (loss) divided by sales.

<sup>(ii)</sup> Refer to section 21. Non-IFRS Financial Measures of this document for the definition of these non-IFRS measures.

<sup>(iii)</sup> Certain comparative figures have been restated to conform with current year presentation.

## 4. RESTRUCTURING AND OTHER RELATED COSTS

During the second quarter of 2022 the Company made organizational changes within the Plant Protein Group to align spending on SG&A including organizational design and advertising and promotional costs with the current expectations of growth in the category. The Company also reviewed the plant protein manufacturing and office space assets in light of its current growth plan and recorded impairment charges related to property and equipment and right-of-use assets that are or will become idle as a result.

During the three months ended June 30, 2022, the Company recorded restructuring and other related costs of \$19.0 million (2021: \$1.2 million). The \$19.0 million consists of \$18.6 million in the Plant Protein Group and \$0.4 million in the Meat Protein Group. Of the \$18.6 million in the Plant Protein Group, \$15.8 million (2021: \$0.0 million) related to asset impairment and \$2.8 million (2021: \$0.0 million) to severance and other employee related costs, as the Company changes focus and reorganizes SG&A and manufacturing operations in response to slower than previously anticipated segment growth. Of the \$0.4 million in the Meat Protein Group, \$1.4 million (2021: \$0.8 million) related to accelerated depreciation, offset by \$1.0 million (2021: \$0.2 million) related to severance and other employee reversals related to the previously announced future closures of the Brampton, Toronto, St. Mary's, and Schomberg poultry plants. The remaining amount of \$0.2 million in 2021 were employee related costs for other organizational restructuring initiatives.

During the six months ended June 30, 2022, the Company recorded restructuring and other related costs of \$22.1 million (2021: \$2.9 million). The \$22.1 million consists of \$18.6 million in the Plant Protein Group and \$3.5 million in the Meat Protein Group. Of the \$18.6 million in the Plant Protein Group, \$15.8 million (2021: \$0.0 million) related to asset impairment and \$2.8 million (2021: \$0.0 million) to severance and other employee related costs, as the Company changes focus and reorganizes SG&A and manufacturing

operations in response to slower than previously anticipated segment growth. Of the \$3.5 million in the Meat Protein Group, \$2.6 million (2021: \$1.7 million) related to accelerated depreciation and \$0.9 million (2021: \$0.8 million) related to severance and other employee costs as a result of the announced future closure of the Schomberg poultry plant as well as the previously announced future closures of the Brampton, Toronto, and St. Mary's poultry plants. The remaining amount of \$0.4 million in 2021 were employee related costs for other organizational restructuring initiatives.

## 5. INCOME TAXES

In the second quarter and the six months ended June 30, 2022, the Company's effective rate of tax recovery differs from the Canadian statutory tax rate of 26.2% primarily due to the Company not recognizing a deferred tax recovery on losses of its Greenleaf Foods, SPC subsidiary incurred after March 31, 2022. The effective rates of tax expense in determining Adjusted Earnings per Share in the second quarter and six months ended June 30, 2022 are 99.6% and 81.3%, respectively. The effective tax rates in determining the Adjusted Earnings per Share in the second quarter and for the six months differ from the Canadian statutory tax rate primarily due to the reason described above.

In the second quarter and the six months ended June 30, 2021, the Company's effective tax rate differs from the Canadian statutory tax rate of 26.2% primarily due to non-deductible expenditures and transaction costs and the geographic mix of earnings and losses. The effective tax rates in determining Adjusted Earnings per Share in the second quarter and six months ended June 30, 2021 are 28.5% and 28.2%, respectively.

## 6. ACQUISITIONS AND DIVESTITURES

There were no acquisitions or divestitures in the three or six months ended June 30, 2022.

On June 25, 2021, the Company completed the acquisition of a poultry processing facility and associated supply from Certm Inc. (formerly Cericola Farms Inc.), a privately held Canadian company for total consideration of \$62.1 million (cash due at closing: \$40.0 million; 2018 deposit of \$20.2 million and working capital adjustments of \$1.9 million). This acquisition concludes the purchase and sale agreement dated June 27, 2018 pursuant to which the Company previously acquired two poultry plants and associated supply, which had been previously recorded as a right-of-use asset with a corresponding lease obligation, with a put/call option to purchase a third processing facility. The Company has financed the transaction using a combination of cash on hand and drawings on existing credit facilities. The acquisition has been accounted for as a business combination. The Company recognized goodwill of \$7.6 million which is attributable to synergies created by expanding the Company's share of regulated input supply.

During the three months ended June 30, 2021, the Company recorded transaction costs of \$0.1 million that have been excluded from the consideration paid and have been recognized as an expense in other expense.

During the six months ended June 30, 2021, the Company recorded transaction costs of \$0.1 million that have been excluded from the consideration paid and have been recognized as an expense in other expense.

As at June 30, 2021 the Company had not finalized the purchase price equation. This was completed during the fourth quarter of 2021. For full details on the acquisition, refer to Note 16 of the Company's unaudited consolidated interim financial statements ("Consolidated Interim Financial Statements").

## 7. CAPITAL RESOURCES

The consumer foods industry in which the Company operates is generally characterized by high sales volume and high turnover of inventories and accounts receivable. In general, accounts receivable and inventories are readily convertible into cash. Investment in working capital is affected by fluctuations in the price of raw materials, seasonal and other market-related fluctuations. The Company has consistently generated a strong base level of operating cash flow, even in periods of higher commodity prices and during the restructuring of its operations. These operating cash flows provide a base of underlying liquidity that the Company supplements with credit facilities and cash on hand to provide longer-term funding and to finance fluctuations in working capital levels.

The Company's cash balance as at June 30, 2022 was \$93.0 million (June 30, 2021: \$58.9 million; December 31, 2021: \$162.0 million). Cash is held in demand and short-term investment deposits with Canadian financial institutions having long-term debt ratings of A or higher.

The composition of long-term debt is shown below:

(\$ thousands) (Unaudited)	As at June 30, 2022	As at June 30, 2021	As at December 31, 2021
Revolving line of credit	\$ 815,000	\$ 440,000	\$ 555,219
U.S. term credit	341,453	328,812	334,828
Canadian term credit	350,000	350,000	350,000
Government loans	7,700	8,288	12,202
<b>Total long-term debt</b>	<b>\$ 1,514,153</b>	<b>\$ 1,127,100</b>	<b>\$ 1,252,249</b>
Current	\$ 1,029	\$ 5,235	\$ 5,176
Non-current	1,513,124	1,121,865	1,247,073
<b>Total long-term debt</b>	<b>\$ 1,514,153</b>	<b>\$ 1,127,100</b>	<b>\$ 1,252,249</b>
<b>Construction Capital<sup>(i)</sup> included in total long-term debt</b>	<b>\$ 637,795</b>	<b>\$ 703,502</b>	<b>\$ 719,216</b>

<sup>(i)</sup> Refer to section 21. Non-IFRS Financial Measures of this document for the definition of this non-IFRS measure.

On June 29, 2022, the Company renewed its syndicated sustainability-linked credit facility (the "Credit Facility"). The Company extended the maturity date of the \$1,300.0 million unsecured committed revolving line of credit to June 29, 2027, and extended the maturity dates of the US\$265.0 million and \$350.0 million unsecured committed term credit facilities to June 29, 2027 and June 29, 2026, respectively. The Credit Facility can be drawn in Canadian or U.S. dollars and bears interest payable monthly, based on Banker's Acceptance and Prime rates for Canadian dollar loans and based on the Secured Overnight Financing Rate ("SOFR") for U.S. dollar loans. The Credit Facility is intended to meet the Company's funding requirements for capital investments in addition to providing appropriate levels of liquidity for general corporate purposes. The interest rate on the Credit Facility may be adjusted up or down based on the Company's performance compared to specified sustainability targets.

In addition to the drawings on the revolving facility and the term credit, as at June 30, 2022 the Company had drawn letters of credit of \$7.9 million on the Credit Facility (June 30, 2021: \$6.7 million; December 31, 2021: \$8.2 million).

The Credit Facility requires the maintenance of certain covenants. As at June 30, 2022, the Company was in compliance with all of these covenants. The primary financial covenant requires that the Company maintain a total debt to capitalization ratio below a specified threshold.

The Company has additional uncommitted credit facilities for issuing letters of credit up to a maximum of \$125.0 million (June 30, 2021: \$125.0 million; December 31, 2021: \$125.0 million). As at June 30, 2022, \$58.6 million in letters of credit had been issued thereon (June 30, 2021: \$66.8 million; December 31, 2021: \$66.8 million).

The Company has various government loans on specific projects, with contractual interest rates ranging from non-interest bearing to 2.9% per annum (June 30, 2021: 0.0% to 2.9%; December 31, 2021: 0.0% to 2.9%). These specific facilities are repayable over various terms and are maturing from 2022 to 2032. As at June 30, 2022, \$7.7 million (June 30, 2021: \$8.3 million; December 31, 2021: \$12.2 million) was outstanding. All of these facilities are committed.

On June 24, 2022, the Company amended its accounts receivable securitization facility (the "Securitization Facility") by extending the maturity to June 24, 2024. The maximum cash advance available to the Company under the Securitization Facility is \$135.0 million (June 30, 2021: \$120.0 million; December 31, 2021: \$120.0 million). The Securitization Facility provides cash funding with a proportion of the Company's receivables being sold, and provides the Company with competitively priced financing and further diversifies its funding sources. Under the Securitization Facility, the Company has sold certain of its trade accounts receivable, with very limited recourse, to an unconsolidated third-party trust financed by an international financial institution with a long-term AA- debt rating, for cash and short-term notes back to the Company. The receivables are sold at a discount to face value based on prevailing money market rates. The Company retains servicing responsibilities for these receivables.

As at June 30, 2022, the Company had \$182.6 million (June 30, 2021: \$165.7 million; December 31, 2021: \$145.6 million) of trade accounts receivable serviced under the Securitization Facility. In return for the sale of its trade receivables, the Company will receive cash of \$135.0 million (June 30, 2021: \$120.0 million; December 31, 2021: \$112.3 million) and notes receivable in the amount of \$47.6 million (June 30, 2021: \$45.7 million; December 31, 2021: \$33.3 million). The notes receivable are non-interest bearing and are settled on the settlement dates of the securitized accounts receivable. Due to the timing of receipts and disbursements, the Company may, from time to time, also record a receivable or payable related to the Securitization Facility. As at June 30, 2022, the Company recorded a net receivable in the amount of \$15.0 million (June 30, 2021: \$20.6 million net receivable; December 31, 2021: \$7.7 million net payable) in notes receivable (June 30, 2021: notes receivable; December 31, 2021: accounts payable and accruals). The facility is accounted for as an off-balance sheet transaction in accordance with International Financial Reporting Standards ("IFRS").

The Securitization Facility is subject to certain restrictions, including the maintenance of covenants. The Company was in compliance with all of the requirements of this facility as at June 30, 2022. If the Securitization Facility were to be terminated, the Company would



recognize the related amounts on the unaudited condensed consolidated interim balance sheets ("Consolidated Interim Balance Sheets") and consider alternative financing if required.

## 8. CAPITAL EXPENDITURES

Capital expenditures for the second quarter were \$89.7 million, compared to \$166.8 million last year and year-to-date capital expenditures for 2022 were \$179.1 million compared to \$351.5 million last year. The decrease in capital expenditures was primarily attributable to reduced spend as the the build-out of the Indianapolis, Indiana plant protein facility and expansion of the Bacon Centre of Excellence in Winnipeg, Manitoba were completed, and the London, Ontario poultry facility nears completion of construction.

The Company's capital expenditure estimate for the full year of 2022 remains unchanged and in the range of \$400 million to \$500 million, with approximately 50% to be comprised of Construction Capital attributable to the construction of the London, Ontario poultry facility and the remainder largely relating to other projects to add growth and capacity in the Prepared Meats business and to expand hog production.

## 9. NORMAL COURSE ISSUER BID

On May 20, 2022 the Toronto Stock Exchange ("TSX") accepted the Company's notice of intention to commence a Normal Course Issuer Bid ("NCIB"), allowing the Company to repurchase, at its discretion, up to 7.5 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company are cancelled. The program commenced on May 25, 2022 and will terminate on May 24, 2023, or on such earlier date as the Company completes its purchases pursuant to the notice of intention. Under this bid, during the three and six months ended June 30, 2022, no shares were repurchased for cancellation.

On May 20, 2021 the Toronto Stock Exchange ("TSX") accepted the Company's notice of intention to commence a Normal Course Issuer Bid ("NCIB"), allowing the Company to repurchase, at its discretion, up to 7.5 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company are cancelled. The program commenced on May 25, 2021 and terminated on May 24, 2022. Under this bid, during the three and six months ended June 30, 2022, no shares were repurchased for cancellation. During the three and six months ended June 30, 2021, no shares were purchased for cancellation.

On May 21, 2020 the TSX accepted the Company's notice of intention to commence an NCIB, allowing the Company to repurchase, at its discretion, up to 7.5 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company are cancelled. The program commenced on May 25, 2020 and was terminated on May 24, 2021. During the three and six months ended June 30, 2021, no shares were purchased for cancellation.

## 10. CASH FLOW AND FINANCING

Cash and cash equivalents were \$93.0 million at the end of the second quarter of 2022, compared to \$58.9 million at the end of the second quarter of 2021, and \$162.0 million as at December 31, 2021. The decrease in cash and cash equivalents for the six months ended June 30, 2022 was primarily due to investment in long-term assets, investment in working capital, and dividend payments, partially offset by cash earnings and loans drawn on the Credit Facility.

### Cash Flow from Operating Activities

Cash from operating activities for the second quarter of 2022 was \$16.5 million compared to \$30.0 million in 2021. The decrease was mainly due to lower earnings, higher interest paid, and a smaller reduction in derivative margins, partially offset by lower investment in working capital.

Cash used in operating activities for the first six months of 2022 was \$68.5 million compared to \$0.3 million in 2021. The increase was mainly due to lower earnings and higher interest paid, partially offset by lower investment in working capital.

### Cash Flow from Investing Activities

Cash used in investing activities for the second quarter of 2022 was \$87.0 million compared to \$205.8 million in 2021. The decrease was mainly due to lower investment in long-term assets, and the 2021 acquisition of a poultry facility.

For the first six months of 2022, cash used in investing activities was \$188.7 million compared to \$370.2 million in 2021. The decrease was mainly due to lower investment in long-term assets.

### Cash Flow from Financing Activities

Cash provided by financing activities for the second quarter of 2022 was \$97.0 million compared to \$133.8 million in 2021. The decrease was primarily due to lower drawings on the Credit Facility, partially offset by purchase of treasury stock and payment of financing fees associated with the Credit Facility renewal.

For the first six months of 2022, cash provided by financing activities was \$188.2 million compared to \$328.5 million in 2021. The decrease was primarily due to smaller drawings on the Credit Facility, partially offset by purchase of treasury stock and payment of financing fees associated with the Credit Facility renewal.

## 11. GOODWILL

The net carrying value for goodwill was \$662.3 million as at June 30, 2022 (June 30, 2021: \$655.4 million; December 31, 2021 \$658.7 million).

At June 30, 2022, the Company performed impairment testing on the Plant Protein Cash Generating Unit ("CGU") group. This test was triggered by the continued slowdown of the long-term growth rates of the Plant Protein Group. No impairment resulted from comparing the carrying value to its recoverable value determined on a Fair Value Less Costs of Disposal ("FVLCD") methodology. FVLCD was based on after-tax discounted cash flows using a five-year projection.

## 12. FINANCIAL INSTRUMENTS

The Company applies hedge accounting as appropriate and uses derivatives and other non-derivative financial instruments to manage its exposures to fluctuations in foreign exchange rates, interest rates, and commodity prices.

During the three months ended June 30, 2022, the Company recorded a pre-tax gain of \$24.0 million (2021: gain of \$5.3 million) on non-designated financial instruments held for trading.

During the six months ended June 30, 2022, the Company recorded a pre-tax gain of \$15.8 million (2021: loss of \$9.5 million) on non-designated financial instruments held for trading.

During the three months ended June 30, 2022, the pre-tax amount of hedge ineffectiveness recognized in cost of goods sold was a gain of \$0.0 million (2021: loss of \$0.0 million).

During the six months ended June 30, 2022, the pre-tax amount of hedge ineffectiveness recognized in cost of goods sold was a gain of \$0.0 million (2021: loss of \$0.0 million).

The table below sets out fair value measurements of derivative financial instruments as at June 30, 2022 using the fair value hierarchy:

<i>(\$ thousands)</i> <i>(Unaudited)</i>	Level 1	Level 2	Level 3	Total
<b>Assets:</b>				
Foreign exchange contracts	\$ —	1,997	—	\$ 1,997
Commodity contracts <sup>(i)</sup>	696	2,016	—	2,712
Interest rate swaps	—	11,216	—	11,216
	<b>\$ 696</b>	<b>15,229</b>	<b>—</b>	<b>\$ 15,925</b>
<b>Liabilities:</b>				
Foreign exchange contracts	\$ —	1,663	—	\$ 1,663
	<b>\$ —</b>	<b>1,663</b>	<b>—</b>	<b>\$ 1,663</b>

<sup>(i)</sup> Level 1 commodity contracts are net settled and recorded as a net asset or liability on the Consolidated Interim Balance Sheets.

There were no transfers between levels for the three and six months ended June 30, 2022 and June 30, 2021.

Determination of fair value and the resulting hierarchy requires the use of observable market data whenever available and is consistent with the methodology used in the Company's 2021 annual audited Consolidated Financial Statements. The classification of a financial instrument in the hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. For financial instruments that are recognized at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization at the end of each reporting period.

### Accumulated other comprehensive income (loss)

During the three months ended June 30, 2022, a gain of \$0.3 million, net of tax of \$0.1 million, was released to net (loss) earnings from accumulated other comprehensive income (loss) and included in the net change for the year (2021: gain of \$0.0 million, net of tax of \$0.0 million).

During the six months ended June 30, 2022, a loss of \$0.7 million, net of tax of \$0.2 million, was released to net (loss) earnings from accumulated other comprehensive income (loss) and included in the net change for the year (2021: loss of \$1.1 million, net of tax of \$0.4 million).

During the three months ended June 30, 2022, the loss on the net investment hedge recorded in other comprehensive income (loss) was \$9.1 million, net of tax of \$1.7 million (2021: gain of \$3.5 million, net of tax of \$0.8 million).

During the six months ended June 30, 2022, the loss on the net investment hedge recorded in other comprehensive income (loss) was \$5.5 million, net of tax of \$1.1 million (2021: gain of \$7.3 million, net of tax of \$1.5 million).

### 13. TRANSACTIONS WITH RELATED PARTIES

The Company sponsors a number of defined benefit, defined contribution and post-retirement benefit plans. During the three and six months ended June 30, 2022, the Company contributed \$8.4 million and \$16.1 million (2021: \$13.4 million and \$21.0 million) to these plans.

The Company's largest shareholder is McCain Capital Inc. ("MCI"). The Company has been informed that Mr. Michael H. McCain, Chief Executive Officer and President of the Company, is the controlling shareholder of MCI. For the three and six months ended June 30, 2022, the Company received services from MCI and companies directly or indirectly owned by MCI in the amount of \$0.8 million and \$1.6 million (2021: \$0.0 million and \$0.0 million), which represented the market value of these transactions. As at June 30, 2022, \$0.4 million (June 30, 2021: \$0.0 million; December 31, 2021: \$0.6 million) was owed to MCI and companies directly or indirectly owned by MCI relating to these transactions.

McCain Financial Advisory Services ("MFAS"), is an entity jointly controlled by individuals including Mr. Michael H. McCain. For the three and six months ended June 30, 2022 and 2021, the Company provided services to and received services from, MFAS for a nominal amount which represented the market value of the transactions.

### 14. SHARE CAPITAL

As at July 28, 2022, there were 124,984,072 common shares issued and outstanding.

### 15. OTHER MATTERS

On August 3, 2022, the Board of Directors approved a quarterly dividend of \$0.20 per share (an increase of \$0.02 per share from the 2021 second quarter dividends), \$0.80 per share on an annual basis, payable September 29, 2022 to shareholders of record at the close of business September 8, 2022. Unless indicated otherwise by the Company at or before the time the dividend is paid, the dividend will be considered an eligible dividend for the purposes of the "Enhanced Dividend Tax Credit System".

### 16. MAPLE LEAF CENTRE FOR ACTION ON FOOD SECURITY

The Maple Leaf Centre for Action on Food Security (the "Centre") is the primary expression of the Company's sustainability strategy pillar of better communities. The Centre is a registered charity working to reduce food insecurity through collaboration with other organizations and individuals, through advocating for critical policies and investing in programs required to make sustainable improvements in food security. Additional information regarding the Centre is available on its website at <https://www.feedopportunity.com>.

## 17. SUMMARY OF QUARTERLY RESULTS

The following is a summary of unaudited quarterly financial information for each quarter in the last two fiscal years:

	Second Quarter		First Quarter		Fourth Quarter		Third Quarter	
(\$ millions) <sup>(i)(v)</sup>	2022	2021	2022	2021	2021	2020	2021	2020
<b>Sales</b>								
Meat Protein Group	\$1,160.2	\$1,117.5	\$1,089.4	\$1,013.7	\$1,085.2	\$1,080.3	\$1,150.3	\$1,014.4
Plant Protein Group	40.8	48.1	44.9	42.6	45.5	52.5	48.0	51.4
Non-allocated <sup>(ii)</sup>	(5.9)	(6.7)	(7.7)	(3.2)	(10.2)	(3.6)	(9.7)	(8.6)
<b>Total Sales</b>	<b>\$1,195.1</b>	<b>\$1,158.9</b>	<b>\$1,126.6</b>	<b>\$1,053.1</b>	<b>\$1,120.5</b>	<b>\$1,129.2</b>	<b>\$1,188.6</b>	<b>\$1,057.2</b>
<b>Gross profit</b>								
Meat Protein Group	\$ 136.0	\$ 167.0	\$ 131.0	\$ 166.1	\$ 152.2	\$ 185.7	\$ 191.5	\$ 160.6
Plant Protein Group	(10.1)	0.3	(6.3)	0.1	(10.0)	0.3	(3.3)	3.4
Non-allocated <sup>(ii)</sup>	(38.7)	(31.7)	29.2	26.7	0.1	(5.7)	(0.1)	64.1
<b>Total Gross profit</b>	<b>\$ 87.2</b>	<b>\$ 135.7</b>	<b>\$ 153.9</b>	<b>\$ 193.0</b>	<b>\$ 142.3</b>	<b>\$ 180.3</b>	<b>\$ 188.2</b>	<b>\$ 228.1</b>
<b>SG&amp;A</b>								
Meat Protein Group	\$ 87.3	\$ 81.2	\$ 88.6	\$ 87.1	\$ 80.2	\$ 94.2	\$ 85.9	\$ 80.7
Plant Protein Group	26.3	29.8	30.8	28.8	39.8	32.5	34.4	46.5
<b>Total SG&amp;A</b>	<b>\$ 113.6</b>	<b>\$ 110.9</b>	<b>\$ 119.5</b>	<b>\$ 115.9</b>	<b>\$ 120.0</b>	<b>\$ 126.8</b>	<b>\$ 120.3</b>	<b>\$ 127.2</b>
<b>Net Earnings (loss)</b>	<b>\$ (54.6)</b>	<b>\$ 8.8</b>	<b>\$ 13.7</b>	<b>\$ 47.7</b>	<b>\$ 1.9</b>	<b>\$ 25.4</b>	<b>\$ 44.5</b>	<b>\$ 66.0</b>
<b>Earnings (Loss) Per Share<sup>(iii)</sup></b>								
Basic	\$ (0.44)	\$ 0.07	\$ 0.11	\$ 0.39	\$ 0.02	\$ 0.20	\$ 0.36	\$ 0.54
Diluted	\$ (0.44)	\$ 0.07	\$ 0.11	\$ 0.38	\$ 0.01	\$ 0.20	\$ 0.35	\$ 0.53
<b>Adjusted Operating Earnings<sup>(iv)</sup></b>								
Meat Protein Group	\$ 57.7	\$ 87.3	\$ 51.0	\$ 79.6	\$ 77.8	\$ 92.0	\$ 107.6	\$ 80.4
Plant Protein Group	(34.0)	(29.1)	(34.9)	(28.1)	(47.8)	(32.3)	(37.1)	(43.1)
<b>Total Adjusted Operating Earnings</b>	<b>\$ 23.6</b>	<b>\$ 58.3</b>	<b>\$ 16.1</b>	<b>\$ 51.5</b>	<b>\$ 30.0</b>	<b>\$ 59.8</b>	<b>\$ 70.6</b>	<b>\$ 37.3</b>
<b>Adjusted EBITDA<sup>(iv)</sup></b>								
Meat Protein Group	\$ 104.1	\$ 131.2	\$ 97.5	\$ 123.9	\$ 120.7	\$ 137.1	\$ 151.3	\$ 123.0
Plant Protein Group	(30.0)	(25.5)	(30.7)	(24.4)	(43.9)	(28.7)	(33.4)	(39.6)
Non-allocated <sup>(ii)</sup>	—	—	—	—	(0.4)	1.3	—	(0.5)
<b>Total Adjusted EBITDA</b>	<b>\$ 74.1</b>	<b>\$ 105.7</b>	<b>\$ 66.8</b>	<b>\$ 99.5</b>	<b>\$ 76.3</b>	<b>\$ 109.6</b>	<b>\$ 118.0</b>	<b>\$ 83.0</b>
<b>Adjusted EBITDA Margin<sup>(iv)</sup></b>								
Meat Protein Group	9.0 %	11.7 %	9.0 %	12.2 %	11.1 %	12.7 %	13.2 %	12.1 %
Plant Protein Group	(73.6)%	(53.1)%	(68.4)%	(57.2)%	(96.6)%	(54.7)%	(69.6)%	(77.0)%
<b>Total Adjusted EBITDA Margin</b>	<b>6.2 %</b>	<b>9.1 %</b>	<b>5.9 %</b>	<b>9.4 %</b>	<b>6.8 %</b>	<b>9.7 %</b>	<b>9.9 %</b>	<b>7.8 %</b>

<sup>(i)</sup> Totals may not add due to rounding.

<sup>(ii)</sup> Non-Allocated includes eliminations of inter-segment sales and associated cost of goods sold, and non-allocated costs which are comprised of income and expenses not separately identifiable to reportable segments or are not part of the measures used by the Company when assessing a segment's operating results.

<sup>(iii)</sup> Per share information is based on amounts attributable to common shareholders.

<sup>(iv)</sup> Refer to section 21. Non-IFRS Financial Measures of this document.

<sup>(v)</sup> Certain comparative figures have been restated to conform with current year presentation.

Fluctuations in quarterly sales can be attributed to changes in pricing, volume, sales mix, and the impact of foreign exchange translation.

Fluctuations in quarterly net earnings can be attributed to similar factors as noted above, pork and poultry industry processing margins, restructuring and other related costs, operating efficiencies, changes in the fair value of derivative and non-derivative financial instruments and biological assets, transitional costs incurred, provision adjustments, gains/losses on disposal of assets and changes in tax regulations.

For an explanation and analysis of quarterly results, refer to the Company's Management's Discussion and Analysis for each of the respective quarterly periods which are filed on SEDAR and also available on the Company's website at [www.mapleleaffoods.com](http://www.mapleleaffoods.com).

## 18. SIGNIFICANT ACCOUNTING POLICIES

### Accounting Standards Adopted During the Period

Beginning on January 1, 2022, the Company adopted certain International Financial Reporting Standards ("IFRS") and amendments. As required by International Accounting Standard ("IAS") 8 *Accounting Policies, Changes in Accounting Estimates and Errors*, the nature and the effect of these changes are disclosed below:

#### *Onerous Contracts - Cost of Fulfilling a Contract*

Beginning January 1, 2022, the Company adopted the amendment to IAS 37 *Provisions, Contingent Liabilities and Contingent Assets*. The amendment specifies that the 'cost of fulfilling' a contract comprises the 'costs that relate directly to the contract'. Costs that relate directly to the contract can either be incremental costs of fulfilling that contract or an allocation of other costs that relate directly to fulfilling that contract. The adoption of the amendment did not have a material impact on the Consolidated Interim Financial Statements.

#### *Annual Improvements to IFRS (2018-2020) Cycle*

Beginning January 1, 2022, the Company adopted the narrow-scope amendments to three standards as part of the IASB annual improvement process. Amendments were made to clarify which fees an entity includes when it applies the '10 per cent' test in assessing whether to derecognize a financial liability in accordance with IFRS 9 *Financial Instruments*. The amendments also remove the requirement in IAS 41 *Agriculture* for entities to exclude taxation cash flows when measuring the fair value of a biological asset using a present value technique. Lastly, an amendment was made to IFRS 1 *First-time Adoption of International Financial Reporting Standards* for subsidiaries as a first-time adopter. The adoption of the amendment did not have a material impact on the Consolidated Interim Financial Statements.

### Accounting Pronouncements Issued But Not Yet Effective

#### *Classification of Liabilities as Current or Non-current*

On January 23, 2020, an amendment was issued to IAS 1 *Presentation of Financial Statements* to address inconsistencies with how entities classify current and non-current liabilities. The amendment serves to address whether debt and other liabilities with an uncertain settlement date should be classified as current or non-current in the Consolidated Interim Balance Sheets. This amendment is effective on January 1, 2023. The Company intends to adopt this amendment in its Consolidated Interim Financial Statements or the annual period beginning January 1, 2023. The extent of the impact of the adoption of this amendment has not yet been determined.

#### *Definition of Accounting Estimates (Amendments to IAS 8)*

On February 12, 2021, the IASB issued *Definition of Accounting Estimates (Amendments to IAS 8)*. The amendments will require the disclosure of material accounting policy information rather than disclosing significant accounting policies and clarifies how to distinguish changes in accounting policies from changes in accounting estimates. The amendments are effective for annual periods beginning on or after January 1, 2023. The Company intends to adopt this amendment in its Consolidated Interim Financial Statements for the annual period beginning January 1, 2023. The extent of the impact of the adoption of this amendment has not yet been determined.

#### *Disclosure Initiative – Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2)*

On February 12, 2021, the IASB issued *Disclosure Initiative – Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements)*. The amendments help companies provide useful accounting policy disclosures. The amendments are effective for annual periods beginning on or after January 1, 2023. The Company intends to adopt this amendment in its Consolidated Interim Financial Statements for the annual period beginning January 1, 2023. The extent of the impact of the adoption of this amendment has not yet been determined.

#### *Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12)*

On May 7, 2021 the IASB issued *Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12)*. The amendments narrowed the scope of the recognition exemption in paragraphs 15 and 24 of IAS 12 *Income Taxes* (recognition exemption) so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences. The amendments are effective for annual reporting periods beginning on or after January 1, 2023. The Company intends to adopt this amendment in its Consolidated Interim Financial Statements for the annual period beginning January 1, 2023. The extent of the impact of the adoption of this amendment has not yet been determined.

All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the Consolidated Financial Statements.

## 19. INTERNAL CONTROLS OVER FINANCIAL REPORTING

There has been no change in the Company's internal control over financial reporting during the period beginning on April 1, 2022 and ended on June 30, 2022, that has materially affected, or is reasonably likely to materially affect, its internal control over financial reporting.

## 20. OUTLOOK

Maple Leaf Foods is a leading consumer protein company, supported by a portfolio of market leading brands, a solid balance sheet and capital structure that provide financial flexibility. Over the last several years, the Company has developed a foundation to pursue compelling growth vectors across its business and to create value for all stakeholders.

### *Meat Protein Group*

In Meat Protein, the Company's strategy is to drive profitable growth. In 2017, Maple Leaf Foods articulated its target to reach an Adjusted EBITDA Margin of 14% - 16% in 2022, assuming normal market conditions, including a pork complex in-line with the 5-year average.

Given the unprecedented market dynamics, marked by a challenging post-pandemic economy, the conflict in Europe, high inflation and significant market and supply chain disruption, Maple Leaf Foods expects that its Meat Protein Group will achieve the following:

- Mid-to-high single digit sales growth in 2022, driven by continued momentum in sustainable meats, leveraging brand leadership, and growth into the U.S. market.
- Adjusted EBITDA Margin expansion to 14% - 16% target range once markets normalize, driven by mix-shift benefits in prepared meats resulting from growth in sustainable meats and brand renovation, as well as operational efficiencies.

### *Plant Protein Group*

- In late 2021, the Company announced that it was re-evaluating its outlook for the Plant Protein Group and launching a comprehensive review of the overall plant protein category. This decision was driven by a pronounced slowdown in growth rates in the category, particularly in the second half of the year, which fueled the Company's imperative to identify and thoroughly assess the causes, near and long-term trends, and overall implications. While the Company's analysis is ongoing, the results to date confirm that the very high category growth rates previously predicted by many industry experts are unlikely to be achieved given current customer feedback, experience, buy rates and household penetration. Based on this new information, the Company believes that the category will continue to grow at more modest, but still attractive rates. Current estimates suggest that the category will grow at an average annual rate of 10% to 15%, making it a \$6 billion to \$10 billion market by 2030. Accordingly, the Company is pivoting its strategy and investment thesis for the Plant Protein Group and has set a new goal to deliver neutral or better Adjusted EBITDA in the latter half of 2023. Work is ongoing to implement this pivot. Given the current size of the Plant Protein Group of approximately US\$150 million of annual revenue in 2021, the expected resultant business model from this strategy would deliver a 30% gross margin, with less than US\$50 million in SG&A, to achieve the stated Adjusted EBITDA target.

### *Capital*

- The Company's capital expenditure estimate for the full year of 2022 remains unchanged and in the range of \$400 million to \$500 million, with approximately 50% to be comprised of Construction Capital attributable to the construction of the London, Ontario poultry facility and the remainder largely relating to other projects to add growth and capacity in the Prepared Meats business and to expand hog production.
- The Company expects the London, Ontario poultry facility to start to deliver approximately \$100 million annually of additional Adjusted EBITDA once fully ramped up which is expected to be by the end of 2023. Additionally, the Company expects the Bacon Centre of Excellence to contribute approximately \$30 million annually of additional Adjusted EBITDA once fully ramped up which is expected to be in the second half of 2023.

The ongoing effects of COVID-19 induced supply chain disruptions and the war in Ukraine are unpredictable and may impact a number of factors that drive growth in the business, including:

- Agricultural commodity and foreign exchange markets;
- Inflationary cost pressures;
- Disruptions in the global supply chain;
- Availability of labour; and
- The balance between retail and foodservice demand.

For more information on the impact of COVID-19 on the business and the associated risks, refer to section 2. Response to COVID-19, and for more information on the factors that may influence future performance, refer to section 22. Forward-Looking Statements.

The execution of the Company's financial and operational priorities are embedded in a commitment to deliver shared value for the benefit of all stakeholders. The Company's guiding pillars to be the "Most Sustainable Protein Company on Earth" include Better Food, Better Care, Better Communities, Better Planet and are core to how Maple Leaf Foods conducts itself. To that end, the Company's priorities include:

- *Better Food* - leading the real food movement and transitioning key brands to 100% "raised without antibiotics".
- *Better Care* - further advancement of animal care, after achieving our transition of all sows under management to open housing systems in 2021.
- *Better Communities* - investing a minimum of approximately 1% of pre-tax profit to advance sustainable food security.
- *Better Planet* - continuing to amplify its commitment to carbon neutrality, while focusing on eliminating waste in any resources it consumes, including food, energy, water, packaging, and time.

## 21. NON-IFRS FINANCIAL MEASURES

The Company uses the following non-IFRS measures: Adjusted Operating Earnings, Adjusted Earnings per Share, Adjusted EBITDA, Adjusted EBITDA Margin, Construction Capital, Net Debt, Free Cash Flow and Return on Net Assets. Management believes that these non-IFRS measures provide useful information to investors in measuring the financial performance of the Company for the reasons outlined below. These measures do not have a standardized meaning prescribed by IFRS and therefore they may not be comparable to similarly titled measures presented by other publicly traded companies and should not be construed as an alternative to other financial measures determined in accordance with IFRS.

### **Adjusted Operating Earnings, Adjusted EBITDA and Adjusted EBITDA Margin**

Adjusted Operating Earnings, Adjusted EBITDA and Adjusted EBITDA Margin are non-IFRS measures used by Management to evaluate financial operating results. Adjusted Operating Earnings is defined as earnings before other income, income taxes and interest expense adjusted for items that are not considered representative of ongoing operational activities of the business and items where the economic impact of the transactions will be reflected in earnings in future periods when the underlying asset is sold or transferred. Adjusted EBITDA is defined as Adjusted Operating Earnings plus depreciation and intangible asset amortization, adjusted for items included in other expense that are considered representative of ongoing operational activities of the business. Adjusted EBITDA Margin is calculated as Adjusted EBITDA divided by sales.

The table below provides a reconciliation of earnings (loss) before income taxes as reported under IFRS in the Consolidated Interim Financial Statements to Adjusted Operating Earnings and Adjusted EBITDA for the three and six months ended June 30, 2022 as indicated below. Management believes that these non-IFRS measures are useful in assessing the performance of the Company's ongoing operations and its ability to generate cash flows to fund its cash requirements, including the Company's capital investment program.

(\$ millions) <sup>(i)</sup> (Unaudited)	Three months ended June 30, 2022				Three months ended June 30, 2021			
	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total
<b>Earnings (loss) before income taxes</b>	\$ 46.4	(55.1)	(50.0)	\$ (58.6)	\$ 86.7	(29.6)	(42.9)	\$ 14.2
Interest expense and other financing costs	—	—	10.8	10.8	—	—	5.7	5.7
Other expense (income)	1.9	0.1	0.5	2.5	(2.0)	0.1	5.5	3.6
Restructuring and other related costs	0.4	18.7	—	19.0	1.2	—	—	1.2
<b>Earnings (loss) from operations</b>	\$ 48.6	(36.4)	(38.7)	\$ (26.4)	\$ 85.9	(29.5)	(31.7)	\$ 24.7
Start-up expenses from Construction Capital <sup>(iii)(iv)</sup>	9.0	2.3	—	11.3	1.5	0.4	—	1.9
Change in fair value of biological assets	—	—	50.0	50.0	—	—	51.9	51.9
Unrealized gain on derivative contracts	—	—	(11.3)	(11.3)	—	—	(20.2)	(20.2)
<b>Adjusted Operating Earnings<sup>(iv)</sup></b>	\$ 57.7	(34.0)	—	\$ 23.6	\$ 87.3	(29.1)	—	\$ 58.3
Depreciation and amortization <sup>(iv)</sup>	48.3	4.1	—	52.4	45.8	3.7	—	49.4
Items included in other income (expense) representative of ongoing operations <sup>(iv)</sup>	(1.9)	(0.1)	—	(1.9)	(1.9)	(0.1)	—	(2.0)
<b>Adjusted EBITDA<sup>(iv)</sup></b>	\$ 104.1	(30.0)	—	\$ 74.1	\$ 131.2	(25.5)	—	\$ 105.7
<b>Adjusted EBITDA Margin<sup>(iv)</sup></b>	9.0 %	(73.6)%	n/a	6.2 %	11.7 %	(53.1)%	n/a	9.1 %

<sup>(i)</sup> Totals may not add due to rounding.

<sup>(ii)</sup> Non-allocated includes eliminations of inter-segment sales and associated cost of goods sold, and non-allocated costs which are comprised of income and expenses not separately identifiable to reportable segments or are not part of the measures used by the Company when assessing a segment's operating results.

<sup>(iii)</sup> Start-up expenses are temporary costs as a result of operating new facilities that are or have been classified as Construction Capital. These costs can include training, product testing, yield and labour efficiency variances, duplicative overheads and other temporary expenses required to ramp-up production.

<sup>(iv)</sup> Certain comparative figures have been restated to conform with current year presentation.

<sup>(v)</sup> 2022 primarily includes certain costs associated with sustainability projects, gains and losses on the sale of long-term assets, legal settlements, and other miscellaneous expenses. 2021 primarily includes certain costs associated with sustainability projects, gains and losses on the sale of long-term assets, and other miscellaneous expenses.



(\$ millions) <sup>(i)</sup> (Unaudited)	Six months ended June 30, 2022				Six months ended June 30, 2021			
	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total
<b>Earnings (loss) before income taxes</b>	\$ 84.2	(92.2)	(29.6)	\$ (37.6)	\$ 162.9	(58.3)	(24.5)	\$ 80.1
Interest expense and other financing costs	—	—	18.5	18.5	—	—	10.7	10.7
Other expense (income)	3.4	0.1	1.6	5.1	(0.9)	0.2	8.9	8.2
Restructuring and other related costs	3.4	18.7	—	22.1	2.9	—	—	2.9
<b>Earnings (loss) from operations</b>	\$ 91.0	(73.5)	(9.5)	\$ 8.0	\$ 164.9	(58.1)	(4.9)	\$ 101.8
Start-up expenses from Construction Capital <sup>(iii)</sup>	17.7	4.5	—	22.2	2.1	1.0	—	3.1
Change in fair value of biological assets	—	—	10.7	10.7	—	—	13.4	13.4
Unrealized gain on derivative contracts	—	—	(1.2)	(1.2)	—	—	(8.5)	(8.5)
<b>Adjusted Operating Earnings<sup>(iv)</sup></b>	\$ 108.7	(68.9)	—	\$ 39.7	\$ 167.0	(57.1)	—	\$ 109.8
Depreciation and amortization <sup>(iv)</sup>	96.3	8.3	—	104.6	91.2	7.4	—	98.7
Items included in other income (expense) representative of ongoing operations <sup>(v)</sup>	(3.4)	(0.1)	—	(3.5)	(3.1)	(0.2)	—	(3.3)
<b>Adjusted EBITDA<sup>(iv)</sup></b>	\$ 201.6	(60.7)	—	\$ 140.9	\$ 255.1	(49.9)	—	\$ 205.2
<b>Adjusted EBITDA Margin<sup>(iv)</sup></b>	9.0%	(70.8)%	n/a	6.1%	12.0%	(55.0)%	n/a	9.3%

<sup>(i)</sup> Totals may not add due to rounding.

<sup>(ii)</sup> Non-allocated includes eliminations of inter-segment sales and associated cost of goods sold, and non-allocated costs which are comprised of income and expenses not separately identifiable to reportable segments or are not part of the measures used by the Company when assessing a segment's operating results.

<sup>(iii)</sup> Start-up expenses are temporary costs as a result of operating new facilities that are or have been classified as Construction Capital. These costs can include training, product testing, yield and labour efficiency variances, duplicative overheads and other temporary expenses required to ramp-up production.

<sup>(iv)</sup> Certain comparative figures have been restated to conform with current year presentation.

<sup>(v)</sup> 2022 primarily includes certain costs associated with sustainability projects, gains and losses on the sale of long-term assets, legal settlements, and other miscellaneous expenses. 2021 primarily includes certain costs associated with sustainability projects, gains and losses on the sale of long-term assets, and other miscellaneous expenses.

### Adjusted Earnings per Share

Adjusted Earnings per Share, a non-IFRS measure, is used by Management to evaluate financial operating results. It is defined as basic earnings per share and is adjusted on the same basis as Adjusted Operating Earnings. The table below provides a reconciliation of basic earnings per share as reported under IFRS in the Consolidated Interim Financial Statements to Adjusted Earnings per Share for the three and six months ended June 30, as indicated below. Management believes this basis is the most appropriate on which to evaluate financial results as they are representative of the ongoing operations of the Company.

(\$ per share) (Unaudited)	Three months ended June 30,		Six months ended June 30,	
	2022	2021	2022	2021
Basic (loss) earnings per share	\$ (0.44)	\$ 0.07	\$ (0.33)	\$ 0.46
Restructuring and other related costs <sup>(i)</sup>	0.13	0.01	0.15	0.02
Items included in other expense not considered representative of ongoing operations <sup>(ii)</sup>	—	0.02	0.01	0.04
Start-up expenses from Construction Capital <sup>(iii)(iv)</sup>	0.07	0.01	0.14	0.02
Change in fair value of biological assets	0.30	0.31	0.06	0.08
Change in unrealized fair value on derivatives	(0.07)	(0.12)	(0.01)	(0.05)
<b>Adjusted Earnings per Share<sup>(iv)(v)</sup></b>	<b>\$ 0.00</b>	<b>\$ 0.29</b>	<b>\$ 0.03</b>	<b>\$ 0.56</b>

<sup>(i)</sup> Includes per share impact of restructuring and other related costs, net of tax.

<sup>(ii)</sup> Primarily includes legal fees and provisions and transaction related costs, net of tax.

<sup>(iii)</sup> Start-up expenses are temporary costs as a result of operating new facilities that are or have been classified as Construction Capital. These costs can include training, product testing, yield and labour efficiency variances, duplicative overheads and other temporary expenses required to ramp-up production.

<sup>(iv)</sup> Certain comparatives figures have been restated to conform with current year presentation.

<sup>(v)</sup> Totals may not add due to rounding.

### Construction Capital

Construction Capital, a non-IFRS measure, is used by Management to evaluate the amount of capital resources invested in specific strategic development projects that are not yet operational. It is defined as investments and related financing charges in projects over \$50.0 million that are related to longer-term strategic initiatives, with no returns expected for at least 12 months from commencement of construction and the asset will be re-categorized from Construction Capital once operational. The current balance of construction capital includes investments in the London, Ontario poultry production facility. The expansion of the Bacon Centre of Excellence in Winnipeg, Manitoba, was completed in the fourth quarter of 2021 and re-categorized. Investments in capacity at the Walker Drive facility in Brampton, Ontario, and the plant protein production facilities in Indiana were completed in the first quarter of 2022 and have been re-categorized. The following table is a summary of Construction Capital activity and debt financing for the periods indicated below.

(\$ thousands) (Unaudited)	2022	2021
<b>Property and equipment and intangibles at January 1</b>	<b>\$ 2,554,483</b>	\$ 2,062,683
Other capital and intangible assets at January 1 <sup>(i)</sup>	<b>1,811,164</b>	1,622,094
<b>Construction Capital at January 1</b>	<b>\$ 743,319</b>	\$ 440,589
Additions <sup>(ii)</sup>	<b>54,776</b>	152,342
Transfers from Construction Capital	<b>(182,210)</b>	—
<b>Construction Capital at March 31</b>	<b>\$ 615,885</b>	\$ 592,931
Additions <sup>(ii)</sup>	<b>49,903</b>	127,822
<b>Construction Capital at June 30<sup>(iii)</sup></b>	<b>\$ 665,788</b>	\$ 720,753
Other capital and intangible assets at June 30 <sup>(i)</sup>	<b>2,007,489</b>	1,786,319
<b>Property and equipment and Intangibles at June 30</b>	<b>\$ 2,623,374</b>	\$ 2,379,250
<b>Construction Capital debt financing<sup>(iv)</sup></b>	<b>\$ 637,795</b>	\$ 703,502

<sup>(i)</sup> Other capital and intangible assets consists of property and equipment and intangibles that do not meet the definition of Construction Capital.

<sup>(ii)</sup> Certain comparative figures have been restated to conform with current year presentation.

<sup>(iii)</sup> As at June 30, 2022, the net book value of construction capital includes \$2.1 million related to intangible assets (June 30, 2021: \$1.4 million; December 31, 2021: \$2.5 million).

<sup>(iv)</sup> Assumed to be fully funded by debt to the extent that the Company has Net Debt outstanding. Construction Capital debt financing excludes interest paid and capitalized.

### Net Debt

The following table reconciles Net Debt to amounts reported under IFRS in the Company's Consolidated Interim Financial Statements as at June 30, as indicated below. The Company calculates Net Debt as cash and cash equivalents, less long-term debt and bank indebtedness. Management believes this measure is useful in assessing the amount of financial leverage employed.

(\$ thousands) (Unaudited)	As at June 30,	
	2022	2021
<b>Cash and cash equivalents</b>	<b>\$ 92,971</b>	\$ 58,878
Current portion of long-term debt	<b>\$ (1,029)</b>	\$ (5,235)
Long-term debt	<b>(1,513,124)</b>	(1,121,865)
<b>Total debt</b>	<b>\$(1,514,153)</b>	\$(1,127,100)
<b>Net Debt</b>	<b>\$(1,421,182)</b>	\$(1,068,222)

### Free Cash Flow

Free Cash Flow, a non-IFRS measure, is used by Management to evaluate cash flow after investing in the maintenance or expansion of the Company's asset base. It is defined as cash provided by operations, less cash additions to long-term assets and capitalized interest. The following table calculates Free Cash Flow for the periods indicated below:

(\$ thousands) (Unaudited)	Three months ended June 30,		Six months ended June 30,	
	2022	2021	2022	2021
Cash provided by (used in) operating activities	<b>\$ 16,492</b>	\$ 29,971	<b>\$ (68,501)</b>	\$ (263)
Additions to long-term assets	<b>(81,935)</b>	(161,273)	<b>(179,240)</b>	(322,240)
Interest paid and capitalized	<b>(5,123)</b>	(4,638)	<b>(9,620)</b>	(8,609)
<b>Free Cash Flow</b>	<b>\$ (70,566)</b>	\$ (135,940)	<b>\$ (257,361)</b>	\$ (331,112)

## Return on Net Assets

Return on Net Assets ("RONA") is calculated by dividing tax effected earnings from operations (adjusted for items which are not considered representative of the underlying operations of the business) by average monthly net assets. Net assets are defined as total assets (excluding cash and deferred tax assets) less non-interest bearing liabilities (excluding deferred tax liabilities). Management believes that RONA is an appropriate basis upon which to evaluate long-term financial performance.

## Quarterly Non-IFRS Financial Measures

(\$ millions) <sup>(i)</sup> (Unaudited)	Three months ended March 31, 2022				Three months ended March 31, 2021			
	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total
<b>Earnings (loss) before income taxes</b>	\$ 37.8	(37.1)	20.4	\$ 21.0	\$ 76.2	(28.7)	18.4	\$ 65.9
Interest expense and other financing costs	—	—	7.7	7.7	—	—	5.0	5.0
Other expense (income)	1.5	—	1.1	2.6	1.1	0.1	3.3	4.5
Restructuring and other related costs	3.0	—	—	3.0	1.7	—	—	1.7
<b>Earnings (loss) from operations</b>	\$ 42.3	(37.1)	29.2	\$ 34.4	\$ 79.0	(28.7)	26.7	\$ 77.1
Start-up expenses from Construction Capital <sup>(iii)(iv)</sup>	8.7	2.2	—	10.9	0.6	0.6	—	1.2
Change in fair value of biological assets	—	—	(39.3)	(39.3)	—	—	(38.5)	(38.5)
Unrealized gain on derivative contracts	—	—	10.1	10.1	—	—	11.8	11.8
<b>Adjusted Operating Earnings<sup>(iv)</sup></b>	\$ 51.0	(34.9)	—	\$ 16.1	\$ 79.6	(28.1)	—	\$ 51.5
Depreciation and amortization <sup>(iv)</sup>	48.0	4.2	—	52.3	45.5	3.8	—	49.2
Items included in other income (expense) representative of ongoing operations <sup>(v)</sup>	(1.5)	—	—	(1.5)	(1.2)	(0.1)	—	(1.3)
<b>Adjusted EBITDA<sup>(iv)</sup></b>	\$ 97.5	(30.7)	—	\$ 66.8	\$ 123.9	(24.4)	—	\$ 99.5
<b>Adjusted EBITDA Margin<sup>(iv)</sup></b>	9.0 %	(68.4)%	n/a	5.9 %	12.2 %	(57.2)%	n/a	9.4 %

(\$ millions) <sup>(i)</sup> (Unaudited)	Three months ended December 31, 2021				Three months ended December 31, 2020			
	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total
<b>Earnings (loss) before income taxes</b>	\$ 67.8	(49.9)	(10.7)	\$ 7.3	\$ 89.4	(32.3)	(21.7)	\$ 35.4
Interest expense and other financing costs	—	—	6.5	6.5	—	—	8.0	8.0
Other expense (income)	3.0	0.1	4.2	7.3	0.9	—	8.0	8.9
Restructuring and other related costs	1.2	—	—	1.2	1.2	—	—	1.2
<b>Earnings (loss) from operations</b>	\$ 72.0	(49.8)	0.1	\$ 22.3	\$ 91.5	(32.3)	(5.7)	\$ 53.5
Start-up expenses from Construction Capital <sup>(iii)(iv)</sup>	5.8	2.0	—	7.7	0.5	—	—	0.5
Change in fair value of biological assets	—	—	(0.3)	(0.3)	—	—	(1.8)	(1.8)
Unrealized gain on derivative contracts	—	—	0.2	0.2	—	—	7.6	7.6
<b>Adjusted Operating Earnings<sup>(iv)</sup></b>	\$ 77.8	(47.8)	—	\$ 30.0	\$ 92.0	(32.3)	—	\$ 59.8
Depreciation and amortization <sup>(iv)</sup>	45.9	4.1	—	49.9	46.5	3.6	—	50.0
Items included in other income (expense) representative of ongoing operations <sup>(v)</sup>	(3.0)	(0.1)	(0.4)	(3.5)	(1.4)	—	1.3	(0.2)
<b>Adjusted EBITDA<sup>(iv)</sup></b>	\$ 120.7	(43.9)	(0.4)	\$ 76.3	\$ 137.1	(28.7)	1.3	\$ 109.6
<b>Adjusted EBITDA Margin<sup>(iv)</sup></b>	11.1 %	(96.6)%	n/a	6.8 %	12.7 %	(54.7)%	n/a	9.7 %

(\$ millions) <sup>(i)</sup> (Unaudited)	Three months ended September 30, 2021				Three months ended September 30, 2020			
	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(ii)</sup>	Total
<b>Earnings (loss) before income taxes</b>	\$ 105.3	(37.9)	(5.2)	\$ 62.3	\$ 79.8	(43.2)	53.7	\$ 90.4
Interest expense and other financing costs	—	—	5.7	5.7	—	—	7.5	7.5
Other expense (income)	(0.6)	0.2	(0.6)	(1.0)	(1.6)	—	2.9	1.4
Restructuring and other related costs	0.8	—	—	0.8	1.7	—	—	1.7
<b>Earnings (loss) from operations</b>	\$ 105.6	(37.7)	(0.1)	\$ 67.9	\$ 80.0	(43.1)	64.1	\$ 100.9
Start-up expenses from Construction Capital <sup>(iii)(iv)</sup>	2.0	0.6	—	2.6	0.4	—	—	0.4
Change in fair value of biological assets	—	—	(6.6)	(6.6)	—	—	(40.2)	(40.2)
Unrealized gain on derivative contracts	—	—	6.7	6.7	—	—	(23.9)	(23.9)
<b>Adjusted Operating Earnings<sup>(iv)</sup></b>	\$ 107.6	(37.1)	—	\$ 70.6	\$ 80.4	(43.1)	—	\$ 37.3
Depreciation and amortization	43.1	3.9	—	47.0	44.1	3.6	—	47.7
Items included in other income (expense) representative of ongoing operations <sup>(v)</sup>	0.6	(0.2)	—	0.4	(1.5)	0.0	(0.5)	(2.0)
<b>Adjusted EBITDA<sup>(iv)</sup></b>	\$ 151.3	(33.4)	—	\$ 118.0	\$ 123.0	(39.6)	(0.5)	\$ 83.0
<b>Adjusted EBITDA Margin<sup>(iv)</sup></b>	13.2 %	(69.6)%	n/a	9.9 %	12.1 %	(77.0)%	n/a	7.8 %

<sup>(i)</sup> Totals may not add due to rounding.

<sup>(ii)</sup> Non-allocated includes eliminations of inter-segment sales and associated cost of goods sold, and non-allocated costs which are comprised of income and expenses not separately identifiable to reportable segments or are not part of the measures used by the Company when assessing a segment's operating results.

<sup>(iii)</sup> Start-up expenses are temporary costs as a result of operating new facilities that are or have been classified as Construction Capital. These costs can include training, product testing, yield and labour efficiency variances, duplicative overheads and other temporary expenses required to ramp-up production.

<sup>(iv)</sup> Certain comparative figures have been restated to conform with current year presentation.

<sup>(v)</sup> 2021 primarily includes certain costs associated with sustainability projects, legal settlements, gains and losses on the sale of long-term assets, and other miscellaneous expenses. 2020 primarily includes certain costs associated with sustainability projects, legal settlements, gains and losses on the sale of long-term assets, and other miscellaneous expenses.

## 22. FORWARD-LOOKING STATEMENTS

This document contains, and the Company's oral and written public communications often contain, "forward-looking information" within the meaning of applicable securities law. These statements are based on current expectations, estimates, projections, beliefs, judgments and assumptions based on information available at the time the applicable forward-looking statement was made and in light of the Company's experience combined with its perception of historical trends. Such statements include, but are not limited to, statements with respect to objectives and goals, in addition to statements with respect to beliefs, plans, targets, goals, objectives, expectations, anticipations, estimates, and intentions. Forward-looking statements are typically identified by words such as "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "could", "would", "believe", "plan", "intend", "design", "target", "undertake", "view", "indicate", "maintain", "explore", "entail", "schedule", "objective", "strategy", "likely", "potential", "outlook", "aim", "propose", "goal", and similar expressions suggesting future events or future performance. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The Company believes the expectations reflected in the forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon.

Specific forward-looking information in this document may include, but is not limited to, statements with respect to:

- implications of COVID-19, including implications for supply chain, workforce availability and consumption patterns;
- future performance, including future financial objectives, goals and targets, category growth analysis, expected capital spend and expected SG&A expenditures for the Company and each of its operating segments;

- the execution of the Company's business strategy, including the development and expected timing of business initiatives, brand expansion and repositioning, plant protein category investment and performance, and other growth opportunities, as well as the impact thereof;
- the impact of international trade conditions and markets on the Company's business, including access to markets, implications associated with the spread of foreign animal disease (such as African Swine Fever ("ASF")) and other animal diseases such as Avian Influenza, as well as other social, economic and political factors that affect trade, including the war in Ukraine;
- competitive conditions and the Company's ability to position itself competitively in the markets in which it competes;
- capital projects, including planning, construction, estimated expenditures, schedules, approvals, expected capacity, in-service dates and anticipated benefits of construction of new facilities and expansions of existing facilities;
- the Company's dividend policy, including future levels and sustainability of cash dividends, the tax treatment thereof and future dividend payment dates;
- the impact of commodity prices on the Company's operations and financial performance, including the use and effectiveness of hedging instruments;
- expected future cash flows and the sufficiency thereof, sources of capital at attractive rates, future contractual obligations, future financing options, renewal of credit facilities, and availability of capital to fund growth plans, operating obligations and dividends;
- operating risks, including the execution, monitoring and continuous improvement of the Company's food safety programs, animal health initiatives and cost reduction initiatives;
- the implementation, cost and impact of environmental sustainability initiatives, as well as the anticipated future cost of remediating environmental liabilities;
- the adoption of new accounting standards and the impact of such adoption on the financial position of the Company;
- expectations regarding pension plan performance, including future pension plan assets, liabilities and contributions; and
- developments and implications of actual or potential legal actions.

Various factors or assumptions are typically applied by the Company in drawing conclusions or making the forecasts, projections, predictions or estimations set out in the forward-looking statements. These factors and assumptions are based on information currently available to the Company, including information obtained by the Company from third-party sources and include but are not limited to the following:

- expectations regarding the impact and future implications of COVID-19 and adaptations in operations, supply chain, customer and consumer behaviour, economic patterns and international trade;
- the competitive environment, associated market conditions and market share metrics, category growth or contraction, the expected behaviour of competitors and customers and trends in consumer preferences;
- the success of the Company's business strategy, including execution of the strategy in the Meat Protein Group and the outcome of the category analysis related to the strategy for the Plant Protein Groups;
- prevailing commodity prices, interest rates, tax rates and exchange rates;
- the impact of the war in Ukraine on international relations, trade and markets, as well as the economic condition of and the sociopolitical dynamics between Canada, the U.S., Japan and China, and the ability of the Company to access markets and source ingredients and other inputs in light of global sociopolitical disruption;
- the spread of foreign animal disease (including ASF and Avian Influenza), preparedness strategies to manage such spread, and implications for all protein markets;
- the availability of capital to fund future capital requirements associated with existing operations, assets and projects;
- expectations regarding participation in and funding of the Company's pension plans;
- the availability of insurance coverage to manage certain liability exposures;
- the extent of future liabilities and recoveries related to legal claims;
- prevailing regulatory, tax and environmental laws; and
- future operating costs and performance, including the Company's ability to achieve operating efficiencies and maintain high sales volumes, high turnover of inventories and high turnover of accounts receivable.

Readers are cautioned that these assumptions may prove to be incorrect in whole or in part. The Company's actual results may differ materially from those anticipated in any forward-looking statements.

Factors that could cause actual results or outcomes to differ materially from the results expressed, implied, or projected in the forward-looking statements contained in this document include, among other things, risks associated with the following:

- implications of COVID-19 on the operations and financial performance of the Company, as well the implications for macro socio-economic trends;
- competition, market conditions and the activities of competitors and customers, including the expansion or contraction of key categories (including plant protein);
- the health status of livestock, including the impact of potential pandemics;
- international trade and access to markets and supplies, as well as social, political and economic dynamics, including the war in Ukraine;
- availability of and access to capital;
- decision respecting the return of capital to shareholders;
- the execution of capital projects, including cost, schedule and regulatory variables;
- food safety, consumer liability and product recalls;
- cyber security and the maintenance and operation of the Company's information systems and processes;
- climate change;
- strategic risk management, including the outcome of the analysis of the plant protein category;
- acquisitions and divestitures;
- fluctuations in the debt and equity markets;
- fluctuations in interest rates and currency exchange rates;
- pension assets and liabilities;
- cyclical nature of the cost and supply of hogs and the competitive nature of the pork market generally;
- the effectiveness of commodity and interest rate hedging strategies;
- impact of changes in the market value of the biological assets and hedging instruments;
- the supply management system for poultry in Canada;
- availability of plant protein ingredients;
- intellectual property, including product innovation, product development, brand strategy and trademark protection;
- consolidation of operations and focus on protein;
- the use of contract manufacturers;
- reputation;
- weather;
- compliance with government regulation and adapting to changes in laws;
- actual and threatened legal claims;
- consumer trends and changes in consumer tastes and buying patterns;
- environmental regulation and potential environmental liabilities;
- consolidation in the retail environment;
- employment matters, including complying with employment laws across multiple jurisdictions, the potential for work stoppages due to non-renewal of collective agreements, recruiting and retaining qualified personnel, reliance on key personnel and succession planning;
- pricing of products;
- managing the Company's supply chain;
- changes in International Financial Reporting Standards and other accounting standards that the Company is required to adhere to for regulatory purposes; and
- other factors as set out under the heading "Risk Factors" in the Company's Management Discussion and Analysis for the year ended December 31, 2021.

The Company cautions readers that the foregoing list of factors is not exhaustive.

Readers are further cautioned that some of the forward-looking information, such as statements concerning future capital expenditures, Adjusted EBITDA Margin growth in the Meat Protein Group, and Adjusted EBITDA target in the Plant Protein Group (including the

timing, pace and impact of restructuring activities), may be considered to be financial outlooks for purposes of applicable securities legislation. These financial outlooks are presented to evaluate potential future earnings and anticipated future uses of cash flows and may not be appropriate for other purposes. Readers should not assume these financial outlooks will be achieved.

More information about risk factors can be found under the heading "Risk Factors" in the Company's Annual Management's Discussion and Analysis for the year ended December 31, 2021, that is available on SEDAR at [www.sedar.com](http://www.sedar.com). The reader should review such section in detail. Additional information concerning the Company, including the Company's Annual Information Form, is available on SEDAR at [www.sedar.com](http://www.sedar.com).

All forward-looking statements included herein speak only as of the date hereof. Unless required by law, the Company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements contained herein are expressly qualified by this cautionary statement.

### **23. ABOUT MAPLE LEAF FOODS INC.**

Maple Leaf Foods is a carbon neutral<sup>(i)</sup> company with a vision to be the most sustainable protein company on earth, responsibly producing food products under leading brands including Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®, Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®, Lightlife® and Field Roast™. The Company employs approximately 13,500 people and does business primarily in Canada, the U.S. and Asia. The Company is headquartered in Mississauga, Ontario and its shares trade on the Toronto Stock Exchange (MFI).

<sup>(i)</sup> See the Company's 2021 Sustainability Report that is available on the Maple Leaf Foods website at <https://www.mapleleaffoods.com/sustainability>.



# Consolidated Interim Financial Statements

Consolidated Interim Balance Sheets	24
Consolidated Interim Statements of Net (Loss) Earnings	25
Consolidated Interim Statements of Other Comprehensive Income (Loss)	26
Consolidated Interim Statements of Changes in Total Equity	27
Consolidated Interim Statements of Cash Flows	28
Notes to the Consolidated Interim Financial Statements	
1 The Company	29
2 Significant Accounting Policies	29
3 Accounts Receivable	30
4 Inventories	31
5 Biological Assets	31
6 Goodwill	31
7 Provisions	32
8 Long-Term Debt	33
9 Share Capital	34
10 Financial Instruments	34
11 Interest Expense and Other Financing Costs	37
12 (Loss) Earnings Per Share	37
13 Share-Based Payment	38
14 Segmented Financial Information	40
15 Related Party Transactions	42
16 Business Combinations	43

# Consolidated Interim Balance Sheets

<i>(In thousands of Canadian dollars)</i> <i>(Unaudited)</i>	<i>Notes</i>	<i>As at June 30,</i> <i>2022</i>	<i>As at June 30,</i> <i>2021<sup>(i)</sup></i>	<i>As at December 31,</i> <i>2021</i>
<b>ASSETS</b>				
				<i>(Audited)</i>
Cash and cash equivalents		\$ 92,971	\$ 58,878	\$ 162,031
Accounts receivable	3	191,199	201,027	167,082
Notes receivable	3	62,609	66,297	33,294
Inventories	4	507,489	442,152	409,677
Biological assets	5	129,181	118,445	138,209
Income taxes recoverable		6,297	1,830	1,830
Prepaid expenses and other assets		50,774	52,810	24,988
Assets held for sale		604	—	—
<b>Total current assets</b>		<b>\$ 1,041,124</b>	<b>\$ 941,439</b>	<b>\$ 937,111</b>
Property and equipment		2,262,609	2,008,904	2,189,165
Right-of-use assets		158,328	180,579	161,662
Investments		22,667	15,370	22,326
Employee benefits		15,873	—	—
Other long-term assets		22,747	8,851	11,644
Deferred tax asset		48,725	24,775	39,907
Goodwill	6	662,261	655,415	658,673
Intangible assets		360,765	370,346	365,318
<b>Total long-term assets</b>		<b>\$ 3,553,975</b>	<b>\$ 3,264,240</b>	<b>\$ 3,448,695</b>
<b>Total assets</b>		<b>\$ 4,595,099</b>	<b>\$ 4,205,679</b>	<b>\$ 4,385,806</b>
<b>LIABILITIES AND EQUITY</b>				
Accounts payable and accruals		\$ 545,432	\$ 500,876	\$ 526,189
Current portion of provisions	7	32,680	886	842
Current portion of long-term debt	8	1,029	5,235	5,176
Current portion of lease obligations		37,522	40,276	31,375
Income taxes payable		—	14,396	23,853
Other current liabilities		43,106	59,862	81,265
<b>Total current liabilities</b>		<b>\$ 659,769</b>	<b>\$ 621,531</b>	<b>\$ 668,700</b>
Long-term debt	8	1,513,124	1,121,865	1,247,073
Lease obligations		142,462	154,457	144,391
Employee benefits		64,964	90,879	97,629
Provisions	7	16,197	44,555	44,650
Other long-term liabilities		2,232	6,022	1,057
Deferred tax liability		176,680	140,957	146,380
<b>Total long-term liabilities</b>		<b>\$ 1,915,659</b>	<b>\$ 1,558,735</b>	<b>\$ 1,681,180</b>
<b>Total liabilities</b>		<b>\$ 2,575,428</b>	<b>\$ 2,180,266</b>	<b>\$ 2,349,880</b>
<b>Shareholders' equity</b>				
Share capital	9	\$ 862,688	\$ 840,230	\$ 847,016
Retained earnings		1,160,951	1,210,225	1,212,244
Contributed surplus		9,969	3,186	5,371
Accumulated other comprehensive income (loss)		11,979	(9,490)	(2,459)
Treasury stock		(25,916)	(18,738)	(26,246)
<b>Total shareholders' equity</b>		<b>\$ 2,019,671</b>	<b>\$ 2,025,413</b>	<b>\$ 2,035,926</b>
<b>Total liabilities and equity</b>		<b>\$ 4,595,099</b>	<b>\$ 4,205,679</b>	<b>\$ 4,385,806</b>

<sup>(i)</sup> Restated, see Note 16(a).

See accompanying Notes to the Consolidated Interim Financial Statements.

# Consolidated Interim Statements of Net (Loss) Earnings

(In thousands of Canadian dollars, except share amounts) (Unaudited)	Notes	Three months ended June 30,		Six months ended June 30,	
		2022	2021	2022	2021
Sales		\$ 1,195,133	\$ 1,158,861	\$ 2,321,686	\$ 2,211,944
Cost of goods sold		1,107,894	1,023,205	2,080,584	1,883,334
Gross profit		\$ 87,239	\$ 135,656	\$ 241,102	\$ 328,610
Selling, general and administrative expenses		113,608	110,924	233,065	226,804
(Loss) earnings before the following:		\$ (26,369)	\$ 24,732	\$ 8,037	\$ 101,806
Restructuring and other related costs	7	19,039	1,190	22,057	2,858
Other expense		2,452	3,617	5,076	8,159
(Loss) earnings before interest and income taxes		\$ (47,860)	\$ 19,925	\$ (19,096)	\$ 90,789
Interest expense and other financing costs	11	10,786	5,711	18,502	10,679
(Loss) earnings before income taxes		\$ (58,646)	\$ 14,214	\$ (37,598)	\$ 80,110
Income tax (recovery) expense		(4,034)	5,440	3,327	23,644
Net (loss) earnings		\$ (54,612)	\$ 8,774	\$ (40,925)	\$ 56,466
(Loss) earnings per share attributable to common shareholders:	12				
Basic (loss) earnings per share		\$ (0.44)	\$ 0.07	\$ (0.33)	\$ 0.46
Diluted (loss) earnings per share		\$ (0.44)	\$ 0.07	\$ (0.33)	\$ 0.45
Weighted average number of shares (millions):	12				
Basic		124.1	123.4	124.0	123.3
Diluted		124.1	125.5	124.0	125.5

See accompanying Notes to the Consolidated Interim Financial Statements.

## Consolidated Interim Statements of Other Comprehensive Income (Loss)

<i>(In thousands of Canadian dollars)</i> <i>(Unaudited)</i>	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2022</b>	2021	<b>2022</b>	2021
Net (loss) earnings	\$ (54,612)	\$ 8,774	\$ (40,925)	\$ 56,466
Other comprehensive income				
Actuarial gains that will not be reclassified to profit or loss (Net of tax of \$0.2 million and \$13.6 million; 2021: \$0.1 million and \$24.9 million)	\$ 505	\$ 233	\$ 39,406	\$ 73,161
Items that are or may be reclassified subsequently to profit or loss:				
Change in accumulated foreign currency translation adjustment (Net of tax of \$0.0 million and \$0.0 million; 2021: \$0.0 million and \$0.0 million)	15,063	(4,685)	\$ 8,092	\$ (10,150)
Change in foreign exchange on long-term debt designated as a net investment hedge (Net of tax of \$1.7 million and \$1.1 million; 2021: \$0.8 million and \$1.5 million)	(9,085)	3,464	(5,525)	7,282
Change in cash flow hedges (Net of tax of \$0.7 million and \$4.1 million; 2021: \$0.5 million and \$2.4 million)	1,907	1,201	11,871	6,792
Total items that are or may be reclassified subsequently to profit or loss	\$ 7,885	\$ (20)	\$ 14,438	\$ 3,924
Total other comprehensive income	\$ 8,390	\$ 213	\$ 53,844	\$ 77,085
Comprehensive (loss) income	\$ (46,222)	\$ 8,987	\$ 12,919	\$ 133,551

See accompanying Notes to the Consolidated Interim Financial Statements.

# Consolidated Interim Statements of Changes in Total Equity

(In thousands of Canadian dollars) (Unaudited)	Notes	Accumulated other comprehensive income (loss) <sup>(i)</sup>							Total equity
		Share capital	Retained earnings	Contributed surplus	Foreign currency translation adjustment	Unrealized gains and losses on cash flow hedges	Unrealized gains on fair value of investments	Treasury stock	
<b>Balance at December 31, 2021</b>		\$ 847,016	1,212,244	5,371	2,037	(7,441)	2,945	(26,246)	\$2,035,926
Net loss		—	(40,925)	—	—	—	—	—	(40,925)
Other comprehensive income (loss) <sup>(ii)</sup>		—	39,406	—	2,567	11,871	—	—	53,844
Dividends declared (\$0.40 per share)		—	(49,774)	—	—	—	—	—	(49,774)
Share-based compensation expense	13	—	—	13,758	—	—	—	—	13,758
Modification of stock compensation plan	13	—	—	(3,594)	—	—	—	—	(3,594)
Deferred taxes on share-based compensation		—	—	(800)	—	—	—	—	(800)
Exercise of stock options		5,888	—	(1,289)	—	—	—	—	4,599
Shares purchased by RSU trust		—	—	—	—	—	—	(7,500)	(7,500)
Settlement of share-based compensation		—	—	(15,560)	—	—	—	7,830	(7,730)
Change in obligation for repurchase of shares	9	9,784	—	12,083	—	—	—	—	21,867
<b>Balance at June 30, 2022</b>		\$ 862,688	1,160,951	9,969	4,604	4,430	2,945	(25,916)	\$2,019,671

(In thousands of Canadian dollars) (Unaudited)	Notes	Accumulated other comprehensive income (loss) <sup>(i)</sup>							Total equity
		Share capital	Retained earnings	Contributed surplus	Foreign currency translation adjustment	Unrealized gains and losses on cash flow hedges	Unrealized gains on fair value of investments	Treasury stock	
Balance at December 31, 2020		\$ 838,969	1,124,973	5,866	3,002	(16,416)	—	(23,930)	\$1,932,464
Net earnings		—	56,466	—	—	—	—	—	56,466
Other comprehensive income (loss) <sup>(ii)</sup>		—	73,161	—	(2,868)	6,792	—	—	77,085
Dividends declared (\$0.36 per share)		—	(44,375)	—	—	—	—	—	(44,375)
Share-based compensation expense	13	—	—	9,229	—	—	—	—	9,229
Deferred taxes on share-based compensation		—	—	(450)	—	—	—	—	(450)
Exercise of stock options	13	1,929	—	—	—	—	—	—	1,929
Settlement of share-based compensation		—	—	(9,679)	—	—	—	5,192	(4,487)
Change in obligation for repurchase of shares		(668)	—	(1,780)	—	—	—	—	(2,448)
<b>Balance at June 30, 2021</b>		\$ 840,230	1,210,225	3,186	134	(9,624)	—	(18,738)	\$2,025,413

<sup>(i)</sup> Items that are or may be subsequently reclassified to profit or loss.

<sup>(ii)</sup> Included in other comprehensive income (loss) is the change in actuarial gains and losses that will not be reclassified to profit or loss and has been reclassified to retained earnings.

See accompanying Notes to the Consolidated Interim Financial Statements.

# Consolidated Interim Statements of Cash Flows

<i>(In thousands of Canadian dollars)</i> <i>(Unaudited)</i>		<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<i>Notes</i>	<b>2022</b>	2021	<b>2022</b>	2021
<b>CASH PROVIDED BY (USED IN):</b>					
<b>Operating activities</b>					
Net (loss) earnings		\$ (54,612)	\$ 8,774	\$ (40,925)	\$ 56,466
Add (deduct) items not affecting cash:					
Change in fair value of biological assets	5	49,963	51,884	10,652	13,409
Depreciation and amortization		57,239	50,199	114,430	100,401
Share-based compensation	13	9,362	4,527	13,758	9,229
Deferred income taxes		(3,160)	(16,054)	4,812	(9,870)
Income tax current		(874)	21,494	(1,485)	33,514
Interest expense and other financing costs	11	10,786	5,711	18,502	10,679
Loss on sale of long-term assets		1,124	406	1,582	693
Impairment of property and equipment and ROU assets		16,056	436	16,056	436
Change in fair value of non-designated derivatives		(14,109)	(18,044)	(12,535)	(8,417)
Change in net pension obligation		1,944	(3,409)	4,442	(26)
Net income taxes paid		(2,875)	(15,426)	(26,487)	(46,703)
Interest paid, net of capitalized interest	11	(22,712)	(5,965)	(30,388)	(11,393)
Change in provision for restructuring and other related costs	7	1,743	(109)	3,456	(68)
Change in derivatives margin		24,784	35,266	(319)	(396)
Other		(6,559)	(4,964)	(7,810)	(1,358)
Change in non-cash operating working capital		(51,608)	(84,755)	(136,242)	(146,859)
Cash provided by (used in) operating activities		\$ 16,492	\$ 29,971	\$ (68,501)	\$ (263)
<b>Investing activities</b>					
Additions to long-term assets		\$ (81,935)	\$ (161,273)	\$ (179,240)	\$ (322,240)
Interest paid and capitalized	11	(5,123)	(4,638)	(9,620)	(8,609)
Acquisition of business	16	—	(40,151)	—	(40,151)
Proceeds from sale of long-term assets		23	215	117	768
Cash used in investing activities		\$ (87,035)	\$ (205,847)	\$ (188,743)	\$ (370,232)
<b>Financing activities</b>					
Dividends paid		\$ (24,901)	\$ (22,267)	\$ (49,774)	\$ (44,375)
Net increase in long-term debt	8	141,085	164,861	255,947	389,722
Payment of lease obligation		(8,682)	(9,290)	(18,090)	(18,681)
Receipt of lease inducement		—	—	6,847	—
Exercise of stock options		881	523	4,599	1,929
Purchase of treasury stock		(7,500)	—	(7,500)	—
Payment of financing fees		(3,845)	(50)	(3,845)	(50)
Cash provided by financing activities		\$ 97,038	\$ 133,777	\$ 188,184	\$ 328,545
<b>Increase (decrease) in cash and cash equivalents</b>		<b>\$ 26,495</b>	<b>\$ (42,099)</b>	<b>\$ (69,060)</b>	<b>\$ (41,950)</b>
Cash and cash equivalents, beginning of period		66,476	100,977	162,031	100,828
Cash and cash equivalents, end of period		\$ 92,971	\$ 58,878	\$ 92,971	\$ 58,878

See accompanying Notes to the Consolidated Interim Financial Statements.

# Notes to the Consolidated Interim Financial Statements

(Tabular amounts in thousands of Canadian dollars unless otherwise indicated)  
Three and Six Months Ended June 30, 2022 and 2021

## 1. THE COMPANY

Maple Leaf Foods Inc. ("Maple Leaf Foods" or the "Company") is a carbon neutral<sup>(i)</sup> company with a vision to be the most sustainable protein company on earth, responsibly producing food products under leading brands including Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®, Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®, Lightlife® and Field Roast™. The Company's portfolio includes prepared meats, ready-to-cook and ready-to-serve meals, snacks kits, value-added fresh pork and poultry, and plant protein products. The address of the Company's registered office is 6985 Financial Dr., Mississauga, Ontario, L5N 0A1, Canada. The unaudited condensed consolidated interim financial statements ("Consolidated Interim Financial Statements") of the Company as at and for the three and six months ended June 30, 2022 include the accounts of the Company and its subsidiaries. The Company's results are organized into two segments: the Meat Protein Group and the Plant Protein Group.

<sup>(i)</sup> See the Company's 2021 Sustainability Report that is available on the Maple Leaf Foods website at <https://www.mapleleaffoods.com/sustainability>.

## 2. SIGNIFICANT ACCOUNTING POLICIES

The Consolidated Interim Financial Statements should be read in conjunction with the Company's 2021 annual audited consolidated financial statements ("2021 Consolidated Financial Statements").

### (a) Statement of Compliance

The Consolidated Interim Financial Statements have been prepared in accordance with International Accounting Standard ("IAS") 34 *Interim Financial Reporting* ("IAS 34") as issued by the International Accounting Standards Board ("IASB") and using the accounting policies, determination of significant estimates and judgments, and corresponding accounting treatments consistent with the Company's 2021 Consolidated Financial Statements, except for new standards adopted during the six months ended June 30, 2022 as described below.

The Consolidated Interim Financial Statements were authorized for issue by the Board of Directors on August 3, 2022.

### (b) Accounting Standards Adopted During the Period

Beginning on January 1, 2022, the Company adopted certain International Financial Reporting Standards ("IFRS") and amendments. As required by IAS 34 and IAS 8 *Accounting Policies, Changes in Accounting Estimates and Errors*, the nature and the effect of these changes are disclosed below:

#### *Onerous Contracts - Cost of Fulfilling a Contract*

Beginning January 1, 2022, the Company adopted the amendment to IAS 37 *Provisions, Contingent Liabilities and Contingent Assets*. The amendment specifies that the 'cost of fulfilling' a contract comprises the 'costs that relate directly to the contract'. Costs that relate directly to the contract can either be incremental costs of fulfilling that contract or an allocation of other costs that relate directly to fulfilling that contract. The adoption of the amendment did not have a material impact on the Consolidated Interim Financial Statements.

#### *Annual Improvements to IFRS (2018-2020) Cycle*

Beginning January 1, 2022, the Company adopted the narrow-scope amendments to three standards as part of the IASB annual improvement process. Amendments were made to clarify which fees an entity includes when it applies the '10 per cent' test in assessing whether to derecognize a financial liability in accordance with IFRS 9 *Financial instruments*. The amendments also remove the requirement in IAS 41 *Agriculture* for entities to exclude taxation cash flows when measuring the fair value of a biological asset using a present value technique. Lastly, an amendment was made to IFRS 1 *First-time Adoption of International Financial Reporting Standards* for subsidiaries as a first-time adopter. The adoption of the amendment did not have a material impact on the Consolidated Interim Financial Statements.

### (c) Accounting Pronouncements Issued But Not Yet Effective

#### *Classification of Liabilities as Current or Non-current*

On January 23, 2020, an amendment was issued to IAS 1 *Presentation of Financial Statements* to address inconsistencies with how entities classify current and non-current liabilities. The amendment serves to address whether debt and other liabilities with an uncertain settlement date should be classified as current or non-current in the consolidated balance sheets. This amendment is effective on January 1, 2023. The Company intends to adopt this amendment in its Consolidated Financial Statements for the annual period beginning January 1, 2023. The extent of the impact of the adoption of this amendment has not yet been determined.

*Definition of Accounting Estimates (Amendments to IAS 8)*

On February 12, 2021, the IASB issued *Definition of Accounting Estimates (Amendments to IAS 8)*. The amendments will require the disclosure of material accounting policy information rather than disclosing significant accounting policies and clarifies how to distinguish changes in accounting policies from changes in accounting estimates. The amendments are effective for annual periods beginning on or after January 1, 2023. The Company intends to adopt this amendment in its Consolidated Financial Statements for the annual period beginning January 1, 2023. The extent of the impact of the adoption of this amendment has not yet been determined.

*Disclosure Initiative – Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2)*

On February 12, 2021, the IASB issued *Disclosure Initiative – Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2 Making Materiality Judgements)*. The amendments help companies provide useful accounting policy disclosures. The amendments are effective for annual periods beginning on or after January 1, 2023. The Company intends to adopt this amendment in its Consolidated Financial Statements for the annual period beginning January 1, 2023. The extent of the impact of the adoption of this amendment has not yet been determined.

*Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12)*

On May 7, 2021 the IASB issued *Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12)*. The amendments narrowed the scope of the recognition exemption in paragraphs 15 and 24 of IAS 12 *Income Taxes* (recognition exemption) so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences. The amendments are effective for annual reporting periods beginning on or after January 1, 2023. The Company intends to adopt this amendment in its Consolidated Financial Statements for the annual period beginning January 1, 2023. The extent of the impact of the adoption of this amendment has not yet been determined.

All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the Consolidated Financial Statements.

**3. ACCOUNTS RECEIVABLE**

	As at June 30, 2022	As at June 30, 2021	As at December 31, 2021
Trade receivables	\$ 145,424	\$ 165,117	\$ 122,030
Less: Allowance for doubtful accounts	(1,745)	(2,335)	(2,041)
Net trade receivables	\$ 143,679	\$ 162,782	\$ 119,989
Other receivables:			
Commodity taxes receivable	15,834	17,994	13,188
Government receivable	20,476	4,789	17,871
Other	11,210	15,462	16,034
	\$ 191,199	\$ 201,027	\$ 167,082

The aging of trade receivables is as follows:

	As at June 30, 2022	As at June 30, 2021	As at December 31, 2021
Current	\$ 116,451	\$ 133,084	\$ 94,110
Past due 0-30 days	25,898	24,672	20,088
Past due 31-60 days	1,391	3,143	3,473
Past due > 60 days	1,684	4,218	4,359
	\$ 145,424	\$ 165,117	\$ 122,030

Trade receivables are impaired when their estimated future cash flows are less than their contractual cash flows. The amount of impairment takes into account the financial condition of the customers, delinquencies in payments, collaterals and credit insurance coverage on the trade receivables.

On June 24, 2022, the Company amended its accounts receivable securitization facility (the "Securitization Facility") by extending the maturity to June 24, 2024. The maximum cash advance available to the Company under the Securitization Facility is \$135.0 million (June 30, 2021: \$120.0 million; December 31, 2021: \$120.0 million). The Securitization Facility provides cash funding with a proportion



of the Company's receivables being sold, and provides the Company with competitively priced financing and further diversifies its funding sources. Under the Securitization Facility, the Company has sold certain of its trade accounts receivable, with very limited recourse, to an unconsolidated third-party trust financed by an international financial institution with a long-term AA- debt rating, for cash and short-term notes back to the Company. The receivables are sold at a discount to face value based on prevailing money market rates. The Company retains servicing responsibilities for these receivables.

As at June 30, 2022, trade accounts receivable being serviced under this program amounted to \$182.6 million (June 30, 2021: \$165.7 million; December 31, 2021: \$145.6 million). In return for the sale of its trade receivables, the Company will receive cash of \$135.0 million (June 30, 2021: \$120.0 million; December 31, 2021: \$112.3 million) and notes receivable in the amount of \$47.6 million (June 30, 2021: \$45.7 million; December 31, 2021: \$33.3 million). The notes receivable are non-interest bearing and are settled on the settlement dates of the securitized accounts receivable. Due to the timing of receipts and disbursements, the Company may, from time to time, also record a receivable or payable related to the Securitization Facility. As at June 30, 2022, the Company recorded a net receivable in the amount of \$15.0 million (June 30, 2021: \$20.6 million net receivable; December 31, 2021: \$7.7 million net payable) in notes receivable (June 30, 2021: notes receivable; December 31, 2021: accounts payable and accruals).

The sale of trade receivables under the Securitization Facility are treated as a sale from an accounting perspective and as a result, trade receivables sold under this facility are derecognized from the unaudited condensed consolidated interim balance sheets ("Consolidated Interim Balance Sheets") as at June 30, 2022 and 2021 and the 2021 annual audited consolidated balance sheets as at December 31, 2021.

#### 4. INVENTORIES

	As at June 30, 2022	As at June 30, 2021	As at December 31, 2021
Raw materials	\$ 89,864	\$ 67,436	\$ 73,580
Work in process	40,656	39,371	33,964
Finished goods	284,461	252,780	217,937
Packaging	25,481	22,496	20,752
Spare parts	67,027	60,069	63,444
	<b>\$ 507,489</b>	<b>\$ 442,152</b>	<b>\$ 409,677</b>

For the three months ended June 30, 2022, inventory in the amount of \$964.3 million (2021: \$912.8 million) was expensed through cost of goods sold.

For the six months ended June 30, 2022, inventory in the amount of \$1,875.7 million (2021: \$1,720.4 million) was expensed through cost of goods sold.

As at June 30, 2022, inventories have been reduced by \$13.7 million (June 30, 2021: \$7.5 million; December 31, 2021: \$10.7 million) as a result of write-downs to net realizable value. The write-downs are included in the amount expensed through cost of goods sold.

#### 5. BIOLOGICAL ASSETS

The change in fair value of commercial hog stock for the three months ended June 30, 2022 was a loss of \$50.0 million (2021: loss of \$51.9 million) and was recorded in cost of goods sold.

The change in fair value of commercial hog stock for the six months ended June 30, 2022 was a loss of \$10.7 million (2021: loss of \$13.4 million) and was recorded in cost of goods sold.

The fair value measures of commercial hog stock have been categorized as a Level 3 fair value based on inputs to the valuation techniques used. There were no transfers between levels for the three and six months ended June 30, 2022 and June 30, 2021.

#### 6. GOODWILL

The net carrying value for goodwill was \$662.3 million as at June 30, 2022 (June 30, 2021: \$655.4 million; December 31, 2021 \$658.7 million).

At June 30, 2022, the Company performed impairment testing on the Plant Protein Cash Generating Unit ("CGU") group. This test was triggered by the continued slowdown of the long-term growth rates of the Plant Protein Group. No impairment resulted from comparing the carrying value to its recoverable value determined on a Fair Value Less Costs of Disposal ("FVLCD") methodology. FVLCD was based on after-tax discounted cash flows using a five-year projection.

## 7. PROVISIONS

	Restructuring and related provisions				Total
	Legal	Environmental	Severance and other employee related costs	Site closing and other cash costs	
<b>Balance at December 31, 2021<sup>(i)</sup></b>	\$ 650	2,449	42,344	49	\$ 45,492
Charges	—	—	3,997	6	4,003
Reversals	—	—	(2,132)	—	(2,132)
Cash payments	(20)	(37)	(103)	(55)	(215)
<b>Balance at March 31, 2022</b>	\$ 630	2,412	44,106	—	\$ 47,148
Charges	—	—	3,004	468	3,472
Reversals	—	—	(1,681)	—	(1,681)
Cash payments	—	(16)	(46)	—	(62)
<b>Balance at June 30, 2022</b>	\$ 630	2,396	45,383	468	\$ 48,877
Current					\$ 32,680
Non-current					16,197
<b>Total at June 30, 2022</b>					\$ 48,877

<sup>(i)</sup> Balance as at December 31, 2021, includes current portion of \$0.8 million and non-current portion of \$44.7 million.

	Restructuring and related provisions				Total
	Legal	Environmental	Severance and other employee related costs	Site closing and other cash costs	
Balance at December 31, 2020	\$ 739	2,621	42,338	61	\$ 45,759
Charges	—	—	1,009	—	1,009
Reversals	—	(140)	(313)	—	(453)
Cash payments	—	(8)	(607)	(49)	(664)
Balance at March 31, 2021	\$ 739	2,473	42,427	12	\$ 45,651
Charges	—	—	717	37	754
Reversals	(89)	—	(340)	—	(429)
Cash payments	—	(13)	(522)	—	(535)
Balance at June 30, 2021	\$ 650	2,460	42,282	49	\$ 45,441
Current					\$ 886
Non-current					44,555
<b>Total at June 30, 2021</b>					\$ 45,441

### Restructuring and Other Related Costs

During the three months ended June 30, 2022, the Company recorded restructuring and other related costs of \$19.0 million (2021: \$1.2 million). The \$19.0 million consists of \$18.6 million in the Plant Protein Group and \$0.4 million in the Meat Protein Group. Of the \$18.6 million in the Plant Protein Group, \$15.8 million (2021: \$0.0 million) related to asset impairment and \$2.8 million (2021: \$0.0 million) to severance and other employee related costs, as the Company changes focus and reorganizes SG&A and manufacturing operations in response to slower than previously anticipated segment growth. Of the \$0.4 million in the Meat Protein Group, \$1.4 million (2021: \$0.8 million) related to accelerated depreciation, offset by \$1.0 million (2021: \$0.2 million) related to severance and other employee reversals related to the previously announced future closures of the Brampton, Toronto, St. Mary's, and Schomberg poultry plants. The remaining amount of \$0.2 million in 2021 were employee related costs for other organizational restructuring initiatives.

During the six months ended June 30, 2022, the Company recorded restructuring and other related costs of \$22.1 million (2021: \$2.9 million). The \$22.1 million consists of \$18.6 million in the Plant Protein Group and \$3.5 million in the Meat Protein Group. Of the \$18.6 million in the Plant Protein Group, \$15.8 million (2021: \$0.0 million) related to asset impairment and \$2.8 million (2021: \$0.0 million) to severance and other employee related costs, as the Company changes focus and reorganizes SG&A and manufacturing operations in response to slower than previously anticipated segment growth. Of the \$3.5 million in the Meat Protein Group, \$2.6 million (2021: \$1.7 million) related to accelerated depreciation and \$0.9 million (2021: \$0.8 million) related to severance and other employee costs as a result of the announced future closure of the Schomberg poultry plant as well as the previously announced future closures of the Brampton, Toronto, and St. Mary's poultry plants. The remaining amount of \$0.4 million in 2021 were employee related costs for other organizational restructuring initiatives.

### 8. LONG-TERM DEBT

	As at June 30, 2022	As at June 30, 2021	As at December 31, 2021
Revolving line of credit	\$ 815,000	\$ 440,000	\$ 555,219
U.S. term credit	341,453	328,812	334,828
Canadian term credit	350,000	350,000	350,000
Government loans	7,700	8,288	12,202
<b>Total long-term debt</b>	<b>\$ 1,514,153</b>	<b>\$ 1,127,100</b>	<b>\$ 1,252,249</b>
Current	\$ 1,029	\$ 5,235	\$ 5,176
Non-current	1,513,124	1,121,865	1,247,073
<b>Total long-term debt</b>	<b>\$ 1,514,153</b>	<b>\$ 1,127,100</b>	<b>\$ 1,252,249</b>

On June 29, 2022, the Company renewed its syndicated sustainability-linked credit facility (the "Credit Facility"). The Company extended the maturity date of the \$1,300.0 million unsecured committed revolving line of credit to June 29, 2027, and extended the maturity dates of the US\$265.0 million and \$350.0 million unsecured committed term credit facilities to June 29, 2027 and June 29, 2026, respectively. The Credit Facility can be drawn in Canadian or U.S. dollars and bears interest payable monthly, based on Banker's Acceptance and Prime rates for Canadian dollar loans and based on the Secured Overnight Financing Rate ("SOFR") for U.S. dollar loans. The Credit Facility is intended to meet the Company's funding requirements for capital investments in addition to providing appropriate levels of liquidity for general corporate purposes. The interest rate on the Credit Facility may be adjusted up or down based on the Company's performance compared to specified sustainability targets.

In addition to the drawings on the revolving facility and the term credit, as at June 30, 2022 the Company had drawn letters of credit of \$7.9 million on the Credit Facility (June 30, 2021: \$6.7 million; December 31, 2021: \$8.2 million).

The Credit Facility requires the maintenance of certain covenants. As at June 30, 2022, the Company was in compliance with all of these covenants. The primary financial covenant requires that the Company maintain a total debt to capitalization ratio below a specified threshold.

The Company has additional uncommitted credit facilities for issuing letters of credit up to a maximum of \$125.0 million (June 30, 2021: \$125.0 million; December 31, 2021: \$125.0 million). As at June 30, 2022, \$58.6 million in letters of credit had been issued thereon (June 30, 2021: \$66.8 million; December 31, 2021: \$66.8 million).

The Company has various government loans on specific projects, with contractual interest rates ranging from non-interest bearing to 2.9% per annum (June 30, 2021: 0.0% to 2.9%; December 31, 2021: 0.0% to 2.9%). These specific facilities are repayable over various terms and are maturing from 2022 to 2032. As at June 30, 2022, \$7.7 million (June 30, 2021: \$8.3 million; December 31, 2021: \$12.2 million) was outstanding. All of these facilities are committed.

The following table reconciles the changes in cash flows from financing activities for long-term debt for the period in the respective years:

	Three months ended June 30,		Six months ended June 30,	
	2022	2021	2022	2021
<b>Total long-term debt, beginning of period</b>	\$ 1,357,212	\$ 966,372	\$ 1,252,249	\$ 745,948
Revolving and term credit facilities - net drawings	\$ 145,645	\$ 165,000	\$ 260,645	\$ 390,000
Government loans - repayments	(4,560)	(139)	(4,698)	(278)
<b>Total cash flow from long-term debt financing activities</b>	\$ 141,085	\$ 164,861	\$ 255,947	\$ 389,722
Foreign exchange revaluation	\$ 15,764	\$ (4,214)	\$ 5,760	\$ (8,732)
Other non-cash changes	92	81	197	162
<b>Total non-cash changes</b>	\$ 15,856	\$ (4,133)	\$ 5,957	\$ (8,570)
<b>Total long-term debt, end of period</b>	\$ 1,514,153	\$ 1,127,100	\$ 1,514,153	\$ 1,127,100

## 9. SHARE CAPITAL

### Share Repurchase

On May 20, 2022 the Toronto Stock Exchange ("TSX") accepted the Company's notice of intention to commence a Normal Course Issuer Bid ("NCIB"), allowing the Company to repurchase, at its discretion, up to 7.5 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company are cancelled. The program commenced on May 25, 2022 and will terminate on May 24, 2023, or on such earlier date as the Company completes its purchases pursuant to the notice of intention. Under this bid, during the three and six months ended June 30, 2022, no shares were repurchased for cancellation.

On May 20, 2021 the Toronto Stock Exchange ("TSX") accepted the Company's notice of intention to commence a Normal Course Issuer Bid ("NCIB"), allowing the Company to repurchase, at its discretion, up to 7.5 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company are cancelled. The program commenced on May 25, 2021 and terminated on May 24, 2022. Under this bid, during the three and six months ended June 30, 2022, no shares were repurchased for cancellation. During the three and six months ended June 30, 2021, no shares were purchased for cancellation.

On May 21, 2020 the TSX accepted the Company's notice of intention to commence an NCIB, allowing the Company to repurchase, at its discretion, up to 7.5 million common shares in the open market or as otherwise permitted by the TSX, subject to the normal terms and limitations of such bids. Common shares purchased by the Company are cancelled. The program commenced on May 25, 2020 and was terminated on May 24, 2021. During the three and six months ended June 30, 2021, no shares were purchased for cancellation.

The Company entered into an Automatic Share Purchase Plan ("ASPP") with a broker that allows the purchase of common shares for cancellation under the NCIB at any time during predetermined trading blackout periods. As at June 30, 2022, an obligation for the repurchase of shares of \$27.2 million (June 30, 2021: \$32.2 million, December 31, 2021: \$49.1 million) was recognized under the ASPP.

## 10. FINANCIAL INSTRUMENTS

The Company applies hedge accounting as appropriate and uses derivatives and other non-derivative financial instruments to manage its exposures to fluctuations in foreign exchange rates, interest rates, and commodity prices.

The fair values and notional amounts of derivative financial instruments as at June 30 are shown below:

	2022			2021		
	Notional amount <sup>(i)</sup>	Fair value		Notional amount <sup>(i)</sup>	Fair value	
		Asset <sup>(ii)</sup>	Liability <sup>(ii)</sup>		Asset <sup>(ii)</sup>	Liability <sup>(ii)</sup>
<b>Cash flow hedges</b>						
Foreign exchange contracts	\$ 93,017	\$ 225	\$ 939	\$ 42,150	\$ 818	\$ 235
Commodity contracts	\$ —	—	—	\$ 14,681	3,352	—
Interest rate swaps	\$ 476,453	11,216	—	\$ 463,812	—	12,301
		\$ 11,441	\$ 939		\$ 4,170	\$ 12,536
<b>Fair value hedges<sup>(iii)</sup></b>						
Foreign exchange contracts	\$ 26,970	\$ 7	\$ 351	\$ 94,083	\$ 2,389	\$ 267
Commodity contracts	\$ 25,133	895	—	\$ 85,334	—	11,545
		\$ 902	\$ 351		\$ 2,389	\$ 11,812
<b>Derivatives not designated in a formal hedging relationship</b>						
Foreign exchange contracts	\$ 120,644	\$ 1,765	\$ 373	\$ 404,591	\$ 3,423	\$ 3,021
Commodity contracts	\$ 296,644	2,016	199	\$ 151,287	8,901	—
		\$ 3,781	\$ 572		\$ 12,324	\$ 3,021
<b>Total fair value</b>		\$ 16,124	\$ 1,862		\$ 18,883	\$ 27,369
Current <sup>(i)(iv)</sup>		\$ 11,593	\$ 1,862		\$ 18,883	\$ 21,346
Non-current <sup>(ii)</sup>		4,531	—		—	6,023
<b>Total fair value</b>		\$ 16,124	\$ 1,862		\$ 18,883	\$ 27,369

<sup>(i)</sup> Unless otherwise stated, notional amounts are stated at the contractual Canadian dollar equivalent.

<sup>(ii)</sup> The current portion of derivative assets and liabilities are recorded in prepaid expenses and other assets and other current liabilities, respectively, in the Consolidated Interim Balance Sheets and will impact profit or loss at various dates within the next 12 months. The non-current portion of derivative assets and liabilities are recorded in other long-term assets and other long-term liabilities, respectively, in the Consolidated Interim Balance Sheets.

<sup>(iii)</sup> The carrying amount of the hedged items in the Consolidated Interim Balance Sheets are recorded at the inverse of the associated hedging instruments and are equal to the accumulated fair value hedge adjustments less hedge ineffectiveness.

<sup>(iv)</sup> As at June 30, 2022, the above fair value of current assets has been decreased by \$0.5 million (June 30, 2021: decreased by \$2.6 million; December 31, 2021: decreased by \$0.5 million), and the above fair value of current liabilities has been decreased by \$0.2 million (June 30, 2021: decreased by \$11.5 million; December 31, 2021: decreased by \$0.0 million) on the Consolidated Interim Balance Sheets, representing the difference in the fair market value of exchange traded commodity contracts and the initial margin requirements. The difference in margin requirements and fair market value is net settled in cash each day with the futures exchange and is recorded within cash and cash equivalents.

During the three months ended June 30, 2022, the Company recorded a pre-tax gain of \$24.0 million (2021: gain of \$5.3 million) on non-designated financial instruments held for trading.

During the six months ended June 30, 2022, the Company recorded a pre-tax gain of \$15.8 million (2021: loss of \$9.5 million) on non-designated financial instruments held for trading.

During the three months ended June 30, 2022, the pre-tax amount of hedge ineffectiveness recognized in cost of goods sold was a gain of \$0.0 million (2021: loss of \$0.0 million).

During the six months ended June 30, 2022, the pre-tax amount of hedge ineffectiveness recognized in cost of goods sold was a gain of \$0.0 million (2021: loss of \$0.0 million).

The table below sets out fair value measurements of derivative financial instruments as at June 30, 2022 using the fair value hierarchy:

	Level 1	Level 2	Level 3	Total
<b>Assets:</b>				
Foreign exchange contracts	\$ —	1,997	—	\$ 1,997
Commodity contracts <sup>(i)</sup>	696	2,016	—	2,712
Interest rate swaps	—	11,216	—	11,216
	<b>\$ 696</b>	<b>15,229</b>	<b>—</b>	<b>\$ 15,925</b>
<b>Liabilities:</b>				
Foreign exchange contracts	\$ —	1,663	—	\$ 1,663
	<b>\$ —</b>	<b>1,663</b>	<b>—</b>	<b>\$ 1,663</b>

<sup>(i)</sup> Level 1 commodity contracts are net settled and recorded as a net asset or liability on the Consolidated Interim Balance Sheets.

There were no transfers between levels for the three and six months ended June 30, 2022 and June 30, 2021.

Determination of fair value and the resulting hierarchy requires the use of observable market data whenever available and is consistent with the methodology used in the 2021 Consolidated Financial Statements. The classification of a financial instrument in the hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. For financial instruments that are recognized at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization at the end of each reporting period.

#### Accumulated other comprehensive income (loss)

The Company estimates that \$4.5 million, net of tax of \$1.5 million, of the unrealized gain included in accumulated other comprehensive income (loss) will be reclassified into net (loss) earnings within the next 12 months. The actual amount of this reclassification will be impacted by future changes in the fair value of financial instruments designated as cash flow hedges. The actual amount reclassified could differ from this estimated amount.

During the three months ended June 30, 2022, a gain of \$0.3 million, net of tax of \$0.1 million, was released to net (loss) earnings from accumulated other comprehensive income (loss) and included in the net change for the year (2021: gain of \$0.0 million, net of tax of \$0.0 million).

During the six months ended June 30, 2022, a loss of \$0.7 million, net of tax of \$0.2 million, was released to net (loss) earnings from accumulated other comprehensive income (loss) and included in the net change for the year (2021: loss of \$1.1 million, net of tax of \$0.4 million).

As at June 30, 2022, the Company had US\$265.0 million (June 30, 2021: US\$265.0 million; December 31, 2021: US\$265.0 million) drawn on the Credit Facility that is designated as a net investment hedge of the Company's U.S. operations. Foreign exchange gains and losses on the designated drawings are recorded in shareholders' equity in accumulated other comprehensive income (loss) and offset translation adjustments on the underlying net assets of the U.S. operations, which are also recorded in accumulated other comprehensive income (loss).

During the three months ended June 30, 2022, the loss on the net investment hedge recorded in other comprehensive income (loss) was \$9.1 million, net of tax of \$1.7 million (2021: gain of \$3.5 million, net of tax of \$0.8 million).

During the six months ended June 30, 2022, the loss on the net investment hedge recorded in other comprehensive income (loss) was \$5.5 million, net of tax of \$1.1 million (2021: gain of \$7.3 million, net of tax of \$1.5 million).

**11. INTEREST EXPENSE AND OTHER FINANCING COSTS**

	Three months ended June 30,		Six months ended June 30,	
	2022	2021	2022	2021
Interest on borrowings from credit facility	\$ 12,508	\$ 6,677	\$ 21,477	\$ 11,863
Interest on lease obligations	1,474	1,879	2,954	3,873
Interest on securitized receivables	594	294	933	496
Interest on government loans	91	80	196	161
Deferred finance charges	416	425	832	849
Credit facility standby fees and other interest	826	994	1,730	2,046
	\$ 15,909	\$ 10,349	\$ 28,122	\$ 19,288
Interest paid and capitalized	(5,123)	(4,638)	(9,620)	(8,609)
	\$ 10,786	\$ 5,711	\$ 18,502	\$ 10,679

Interest paid during the three and six months ended June 30, 2022 was \$27.8 million and \$40.0 million (2021: \$10.6 million and \$20.0 million).

**12. (LOSS) EARNINGS PER SHARE**

Basic (loss) earnings per share amounts are calculated by dividing the net (loss) earnings of the Company by the weighted average number of shares outstanding during the year.

Diluted (loss) earnings per share amounts are calculated by dividing the net (loss) earnings of the Company by the weighted average number of shares outstanding during the year, adjusted for the effects of potentially dilutive instruments.

The following table sets forth the calculation of basic and diluted (loss) earnings per share ("EPS"):

	2022			2021		
	Net loss	Weighted average number of shares <sup>(i)</sup>	EPS	Net earnings	Weighted average number of shares <sup>(i)</sup>	EPS
<i>Three months ended June 30,</i>						
Basic	\$ (54,612)	124.1	\$ (0.44)	\$ 8,774	123.4	\$ 0.07
Stock options <sup>(ii)</sup>		—			2.1	
Diluted	\$ (54,612)	124.1	\$ (0.44)	\$ 8,774	125.5	\$ 0.07
<i>Six months ended June 30,</i>						
Basic	\$ (40,925)	124.0	\$ (0.33)	\$ 56,466	123.3	\$ 0.46
Stock options <sup>(ii)</sup>		—			2.2	
Diluted	\$ (40,925)	124.0	\$ (0.33)	\$ 56,466	125.5	\$ 0.45

<sup>(i)</sup> In millions.

<sup>(ii)</sup> Excludes the effect of approximately 5.4 million (2021: 3.2 million) options and performance shares that are anti-dilutive for the three months ended June 30, 2022 and 4.6 million (2021: 3.2 million) for the six months ended June 30, 2022 that are anti-dilutive.

### 13. SHARE-BASED PAYMENT

#### Stock Options

A summary of the status of the Company's outstanding stock options six months ended June 30 are presented below:

	2022		2021	
	Options outstanding	Weighted average exercise price	Options outstanding	Weighted average exercise price
<b>Outstanding at January 1</b>	<b>6,076,750</b>	<b>\$ 26.22</b>	5,889,550	\$ 25.48
Granted	730,500	\$ 28.20	1,241,250	\$ 25.10
Exercised	(164,970)	\$ 22.53	(63,900)	\$ 21.26
<b>Outstanding at March 31</b>	<b>6,642,280</b>	<b>\$ 26.53</b>	7,066,900	\$ 25.45
Granted	—	\$ —	10,500	\$ 25.10
Exercised	(355,200)	\$ 22.52	(24,050)	\$ 23.04
Forfeited	—	\$ —	(11,100)	\$ 28.38
<b>Outstanding at June 30</b>	<b>6,287,080</b>	<b>\$ 26.76</b>	7,042,250	\$ 25.46
<b>Options currently exercisable</b>	<b>4,230,230</b>	<b>\$ 27.25</b>	4,463,350	\$ 25.80

All outstanding stock options vest and become exercisable over a period not exceeding five years (time vesting) from the date of grant. The outstanding options have a term of seven years.

At grant date, each option series is measured at fair value based on the Black-Scholes formula. Expected volatility is estimated by considering historic average share price volatility. The inputs used in this model for the options granted during the six months ended June 30, 2022 and 2021 are shown in the table below<sup>(i)</sup>:

	Six months ended June 30,	
	2022	2021
Share price at grant date	\$29.91	\$26.38
Exercise price	\$28.20	\$25.10
Expected volatility	28.4%	26.4%
Option life (in years) <sup>(ii)</sup>	4.5	4.5
Expected dividend yield	3.3%	2.7%
Risk-free interest rate <sup>(iii)</sup>	2.0%	0.6%

<sup>(i)</sup> Weighted average based on number of units granted.

<sup>(ii)</sup> Expected weighted average life.

<sup>(iii)</sup> Based on Government of Canada bonds.

There were no stock options granted during the three months ended June 30, 2022 (2021: \$0.1 million). Expenses relating to current and prior year options during the three months ended June 30, 2022 were \$1.2 million (2021: \$1.3 million).

The fair value of options granted during the six months ended June 30, 2022 was \$4.2 million (2021: \$5.7 million). Expenses relating to current and prior year options during the six months ended June 30, 2022 were \$2.3 million (2021: \$2.5 million).



### Restricted Share Units and Performance Share Units

A summary of the status of the Company's Restricted Share Units ("RSUs") plans (including Performance Share Units ("PSUs")) as at and for the six months ended June 30 are presented below:

	2022		2021	
	RSUs outstanding	Weighted average fair value at grant	RSUs outstanding	Weighted average fair value at grant
<b>Outstanding at January 1</b>	<b>1,742,421</b>	<b>\$ 23.59</b>	1,550,135	\$ 24.99
Granted	659,980	\$ 27.11	548,050	\$ 24.12
Forfeited	(4,307)	\$ 23.79	(4,760)	\$ 23.45
<b>Outstanding at March 31</b>	<b>2,398,094</b>	<b>\$ 24.56</b>	2,093,425	\$ 24.76
Granted	39,940	\$ 24.70	—	\$ —
Distributed	(498,842)	\$ 26.52	(319,791)	\$ 30.61
Forfeited	(18,414)	\$ 23.90	(54,933)	\$ 27.98
<b>Outstanding at June 30</b>	<b>1,920,778</b>	<b>\$ 24.06</b>	1,718,701	\$ 23.57

The fair value of RSUs and PSUs granted during the three months ended June 30, 2022 was \$0.8 million (2021: \$0.0 million). Expenses for the three months ended June 30, 2022 relating to current and prior year RSUs and PSUs, were \$6.8 million (2021: \$3.2 million), of which includes a net reduction in expense of \$1.0 million (2021: \$0.0 million) related to cash settled units and the remainder of the net expense will be settled in shares.

The fair value of RSUs and PSUs granted during the six months ended June 30, 2022 was \$15.9 million (2021: \$11.4 million). Expenses for the six months ended June 30, 2022 relating to current and prior year RSUs and PSUs were \$11.0 million (2021: \$6.3 million), of which \$0.4 million (2021: \$0.0 million) will be paid in cash and the remainder settled in shares.

During the six months ended June 30, 2022 the Company stated its intention to settle a portion of the outstanding Restricted Share Units and Performance Share Units in cash, and an amount of \$4.3 million was re-classified from equity to other liabilities. The total liability recorded for these units is \$2.2 million.

The key assumptions used in the valuation of fair value of RSUs granted during the six months ended June 30, 2022 and 2021 are shown in the table below<sup>(i)</sup>:

	2022	2021
Expected RSU life (in years)	3.1	3.2
Forfeiture rate	15.5%	13.9%
Risk-free interest rate <sup>(ii)</sup>	2.0%	0.5%

<sup>(i)</sup> Weighted average based on number of units granted.

<sup>(ii)</sup> Based on Government of Canada bonds.

### Deferred Share Units

Expenses for the three and six months ended June 30, 2022 relating to director share units were \$0.4 million and \$0.8 million (2021: \$0.0 million and \$0.4 million).

#### 14. SEGMENTED FINANCIAL INFORMATION

The Company has two reportable segments. As described below, these segments offer different products, with separate organizational structures, brands, financial, and marketing strategies. The Company's chief operating decision makers regularly review internal reports for these businesses; performance of the Meat Protein Group is based on revenue growth, Adjusted Operating Earnings and Adjusted EBITDA, while the performance of the Plant Protein Group is based predominantly on revenue growth rates, gross margin optimization and controlling selling, general and administrative ("SG&A") investment levels, which generate high revenue growth rates. Refer to section 21. Non-IFRS Financial Measures, of the Company's Management's Discussion and Analysis for the three and six months ended June 30, 2022, for the definitions of these non-IFRS financial measures. The operations of each segment are described as follows:

- (a) The Meat Protein Group is comprised of prepared meats, ready-to-cook and ready-to-serve meals, value-added fresh pork and poultry products that are sold to retail, foodservice and industrial channels, and agricultural operations in pork and poultry. The Meat Protein Group includes leading brands such as Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®, Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®, and many leading regional brands.
- (b) The Plant Protein Group is comprised of refrigerated plant protein products, premium grain-based protein and vegan cheese products sold to retail, foodservice and industrial channels. The Plant Protein Group includes the brands Lightlife® and Field Roast™.

	Three months ended June 30, 2022				Three months ended June 30, 2021			
	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(i)</sup>	Total <sup>(ii)</sup>	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(i)</sup>	Total <sup>(ii)</sup>
<b>Sales</b>	\$1,160,243	40,824	(5,934)	\$1,195,133	\$1,117,458	48,077	(6,674)	\$1,158,861
<b>Gross profit (loss)</b>	\$ 135,970	(10,076)	(38,655)	\$ 87,239	\$ 167,041	267	(31,652)	\$ 135,656
<b>Selling, general and administrative expenses</b>	\$ 87,327	26,282	—	\$ 113,608	\$ 81,172	29,752	—	\$ 110,924
<b>Earnings (loss) before income taxes</b>	\$ 46,390	(55,083)	(49,955)	\$ (58,646)	\$ 86,704	(29,593)	(42,897)	\$ 14,214
Interest expense and other financing costs	—	—	10,786	10,786	—	—	5,711	5,711
Other expense (income)	1,866	72	514	2,452	(2,024)	107	5,534	3,617
Restructuring and other related costs	387	18,653	—	19,039	1,190	—	—	1,190
<b>Earnings (loss) from operations</b>	\$ 48,643	(36,358)	(38,655)	\$ (26,369)	\$ 85,870	(29,486)	(31,652)	\$ 24,732
Start-up expenses from Construction Capital <sup>(iii)(iv)</sup>	9,022	2,314	—	11,336	1,464	421	—	1,885
Change in fair value of biological assets	—	—	49,963	49,963	—	—	51,884	51,884
Unrealized gain on derivative contracts	—	—	(11,308)	(11,308)	—	—	(20,232)	(20,232)
<b>Adjusted Operating Earnings<sup>(iv)</sup></b>	\$ 57,665	(34,044)	—	\$ 23,622	\$ 87,334	(29,065)	—	\$ 58,269
Depreciation and amortization <sup>(iv)</sup>	48,293	4,084	—	52,378	45,770	3,655	—	49,425
Items included in other (expense) income representative of ongoing operations	(1,866)	(71)	—	(1,938)	(1,898)	(106)	—	(2,005)
<b>Adjusted EBITDA<sup>(iv)</sup></b>	\$ 104,092	(30,031)	—	\$ 74,062	\$ 131,206	(25,516)	—	\$ 105,689

<sup>(i)</sup> Non-Allocated includes eliminations of inter-segment sales and associated cost of goods sold, and non-allocated costs which are comprised of income and expenses not separately identifiable to reportable segments or are not part of the measures used by the Company when assessing a segment's operating results.

<sup>(ii)</sup> Totals may not add due to rounding.

<sup>(iii)</sup> Start-up expenses are temporary costs as a result of operating new facilities that are or have been classified as Construction Capital. These costs include but are not limited to training, product testing, yield and labour efficiency variances, duplicative overheads and other temporary expenses required to ramp-up production.

<sup>(iv)</sup> Certain comparative figures have been restated to conform with current year presentation.

	Six months ended June 30, 2022				Six months ended June 30, 2021			
	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(i)</sup>	Total <sup>(ii)</sup>	Meat Protein Group	Plant Protein Group	Non-Allocated <sup>(i)</sup>	Total <sup>(ii)</sup>
<b>Sales</b>	\$2,249,608	85,702	(13,624)	\$2,321,686	\$2,131,171	90,681	(9,908)	\$2,211,944
<b>Gross profit (loss)</b>	\$ 266,930	(16,339)	(9,489)	\$ 241,102	\$ 333,139	409	(4,938)	\$ 328,610
<b>Selling, general and administrative expenses</b>	\$ 175,951	57,114	—	\$ 233,065	\$ 168,253	58,551	—	\$ 226,804
<b>Earnings (loss) before income taxes</b>	\$ 84,199	(92,210)	(29,588)	\$ (37,598)	\$ 162,914	(58,308)	(24,496)	\$ 80,110
Interest expense and other financing costs	—	—	18,502	18,502	—	—	10,679	10,679
Other expense (income)	3,375	104	1,597	5,076	(886)	166	8,879	8,159
Restructuring and other related costs	3,405	18,653	—	22,057	2,858	—	—	2,858
<b>Earnings (loss) from operations</b>	\$ 90,979	(73,453)	(9,489)	\$ 8,037	\$ 164,886	(58,142)	(4,938)	\$ 101,806
Start-up expenses from Construction Capital <sup>(iii)(iv)</sup>	17,674	4,538	—	22,212	2,064	997	—	3,061
Change in fair value of biological assets	—	—	10,652	10,652	—	—	13,409	13,409
Unrealized gain on derivative contracts	—	—	(1,163)	(1,163)	—	—	(8,471)	(8,471)
<b>Adjusted Operating Earnings<sup>(iv)</sup></b>	\$ 108,653	(68,915)	—	\$ 39,738	\$ 166,950	(57,145)	—	\$ 109,805
Depreciation and amortization <sup>(iv)</sup>	96,332	8,300	—	104,632	91,247	7,408	—	98,655
Items included in other (expense) income representative of ongoing operations	(3,375)	(104)	—	(3,479)	(3,130)	(166)	—	(3,296)
<b>Adjusted EBITDA<sup>(iv)</sup></b>	\$ 201,610	(60,719)	—	\$ 140,891	\$ 255,067	(49,903)	—	\$ 205,164

<sup>(i)</sup> Non-Allocated includes eliminations of inter-segment sales and associated cost of goods sold, and non-allocated costs which are comprised of income and expenses not separately identifiable to reportable segments or are not part of the measures used by the Company when assessing a segment's operating results.

<sup>(ii)</sup> Totals may not add due to rounding.

<sup>(iii)</sup> Start-up expenses are temporary costs as a result of operating new facilities that are or have been classified as Construction Capital. These costs include but are not limited to training, product testing, yield and labour efficiency variances, duplicative overheads and other temporary expenses required to ramp-up production.

<sup>(iv)</sup> Certain comparative figures have been restated to conform with current year presentation.

The following summarizes capital expenditures by segments:

	Three months ended June 30,		Six months ended June 30,	
	2022	2021	2022	2021
Meat Protein Group	\$ 82,221	\$ 147,983	\$ 164,094	\$ 292,286
Plant Protein Group	3,653	15,841	7,524	53,859
Non-allocated capital expenditures	3,825	2,954	7,457	5,345
<b>Total capital expenditures</b>	\$ 89,699	\$ 166,778	\$ 179,075	\$ 351,490

### Information About Geographic Areas

The following summarizes sales by country of origin:

	Three months ended June 30,		Six months ended June 30,	
	2022	2021 <sup>(i)</sup>	2022	2021 <sup>(i)</sup>
Canada	\$ 886,870	\$ 842,523	\$ 1,716,831	\$ 1,613,623
U.S.	149,102	141,571	297,089	265,972
Japan	102,370	105,959	201,043	205,141
Other	56,791	68,808	106,723	127,208
<b>Sales</b>	<b>\$ 1,195,133</b>	<b>\$ 1,158,861</b>	<b>\$ 2,321,686</b>	<b>\$ 2,211,944</b>

<sup>(i)</sup> Certain comparatives figures have been restated to conform with current year presentation.

The following summarizes the location of non-current assets by country:

	As at June 30,	As at June 30,	As at December 31,
	2022	2021	2021
Canada	\$ 2,989,331	\$ 2,795,602	\$ 2,910,048
U.S.	479,257	428,573	478,062
Other	703	1,105	963
<b>Total non-current assets<sup>(i)</sup></b>	<b>\$ 3,469,291</b>	<b>\$ 3,225,280</b>	<b>\$ 3,389,073</b>

<sup>(i)</sup> Excludes financial instruments, investments designated as financial instruments, employee benefits, and deferred tax assets.

### Information About Major Customers

For the three months ended June 30, 2022, the Company reported Meat and Plant Protein sales to two customers representing 11.6% and 10.9% (2021: 11.9% and 11.1%) of total sales. No other sales were made to any one customer that represented in excess of 10.0% of total sales.

For the six months ended June 30, 2022, the Company reported Meat and Plant Protein sales to two customers representing 11.6% and 11.1% (2021: 12.3% and 11.5%) of total sales. No other sales were made to any one customer that represented in excess of 10.0% of total sales.

### 15. RELATED PARTY TRANSACTIONS

The Company sponsors a number of defined benefit, defined contribution and post-retirement benefit plans. During the three and six months ended June 30, 2022, the Company contributed \$8.4 million and \$16.1 million (2021: \$13.4 million and \$21.0 million) to these plans.

The Company's largest shareholder is McCain Capital Inc. ("MCI"). The Company has been informed that Mr. Michael H. McCain, Chief Executive Officer and President of the Company, is the controlling shareholder of MCI. For the three and six months ended June 30, 2022, the Company received services from MCI and companies directly or indirectly owned by MCI in the amount of \$0.8 million and \$1.6 million (2021: \$0.0 million and \$0.0 million), which represented the market value of these transactions. As at June 30, 2022, \$0.4 million (June 30, 2021: \$0.0 million; December 31, 2021: \$0.6 million) was owed to MCI and companies directly or indirectly owned by MCI relating to these transactions.

McCain Financial Advisory Services ("MFAS"), is an entity jointly controlled by individuals including Mr. Michael H. McCain. For the three and six months ended June 30, 2022 and 2021, the Company provided services to and received services from, MFAS for a nominal amount which represented the market value of the transactions.

## 16. BUSINESS COMBINATIONS

### (a) 2021 Acquisition

On June 25, 2021, the Company completed the acquisition of a poultry processing facility and associated supply from Certm Inc. (formerly Cericola Farms Inc.), a privately held Canadian company for total consideration of \$62.1 million (cash due at closing: \$40.0 million; 2018 deposit of \$20.2 million and working capital adjustments of \$1.9 million). This acquisition concludes the purchase and sale agreement dated June 27, 2018 pursuant to which the Company previously acquired two poultry plants and associated supply, which had been previously recorded as a right-of-use asset with a corresponding lease obligation, with a put/call option to purchase a third processing facility. The Company has financed the transaction using a combination of cash on hand and drawings on existing credit facilities. The acquisition has been accounted for as a business combination. The Company recognized goodwill of \$7.6 million which is attributable to synergies created by expanding the Company's share of regulated input supply.

The Company finalized the amounts recorded in the business combination during the fourth quarter of 2021.

The final fair value of the consideration transferred for the poultry processing facility and associated poultry supply consists of the following:

	<b>Purchase Price</b>
	<b>June 25, 2021</b>
Purchase price paid upon closing of the put option	\$ 40,000
Cash deposit prepaid in the year ended December 31, 2018	20,185
Working capital and other adjustments	1,928
<b>Total consideration paid in cash</b>	<b>\$ 62,113</b>

During the fourth quarter of 2021 the Company finalized amounts recorded in the business combination which resulted in the following adjustments to the preliminary purchase price allocation:

	<b>June 25, 2021</b>		
	<b>Preliminary amounts</b>	<b>Adjustments</b>	<b>Final amounts</b>
<b>Current assets</b>			
Accounts receivable <sup>(i)</sup>	\$ 1,339	—	\$ 1,339
Prepaid and other assets	70	—	70
<b>Non-current assets</b>			
Property and equipment	13,651	(2,549)	11,102
Intangible assets - poultry quota	46,155	(3,317)	42,838
Goodwill	—	7,643	7,643
<b>Current liabilities</b>			
Accounts payable and accruals	(879)	—	(879)
<b>Total net assets acquired</b>	<b>\$ 60,336</b>	<b>1,777</b>	<b>\$ 62,113</b>

<sup>(i)</sup> Pertain to trade receivables for which contractual cash flows not expected to be collected are not significant.

### (b) Transaction Costs

During the three months ended June 30, 2021, the Company recorded transaction costs of \$0.1 million that have been excluded from the consideration paid and have been recognized as an expense in other expense.

During the six months ended June 30, 2021, the Company recorded transaction costs of \$0.1 million that have been excluded from the consideration paid and have been recognized as an expense in other expense.

There were no transaction costs recorded in 2022.